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Summary 
 
Multidrug resistant strains of Staphylococcus aureus is presenting an increasing threat, 
especially immune compromised individuals. Many of these strains have developed resistance 
to newly approved drugs such as quinupristin-dalfopristin, linezolid and daptomycin. The 
search for alternative treatment, including bacteriocins (ribosomally synthesized antimicrobial 
peptides) of lactic acid bacteria is increasing . 
 
Lactococcus lactis subsp. lactis F10, isolated from freshwater catfish, produced a new nisin 
variant active against clinical strains of S. aureus. The operon encoding nisin F is located on a 
plasmid and the structural gene has been sequenced. The lantibiotic is closely related to nisin 
Z, except at position 30 where valine replaced isoleucine. 
 
The antimicrobial activity of nisin F against S. aureus was tested in the respiratory tract of 
Wistar rats. Non-immunosuppressed and immunosuppressed rats were intranasally infected 
with S. aureus K and then treated with either nisin F or sterile physiological saline. Nisin F 
protected immunosuppressed rats against S. aureus, as symptoms of an infection were only 
detected in the trachea and lungs of immunosuppressed rats treated with saline. The safety of 
intranasally administered nisin F was also evaluated and proved to have no adverse side 
effects. 
 
The potential of nisin F as an antimicrobial agent to treat subcutaneous skin infections was 
evaluated by infecting C57BL/6 mice with a bioluminescent strain of S. aureus (Xen 36). 
Immunosuppressed mice were treated with either nisin F or sterile physiological saline 24 h 
and 48 h after infection with subcutaneously injected S. aureus Xen 36. Histology and 
bioluminescence flux measurements revealed that nisin F was ineffective in the treatment of  
deep dermal staphylococcal infections. Non-infected and infected mice treated with nisin F 
had an influx of polymorphonuclear cells in the deep stroma of the skin tissue. This suggested 
that nisin F, when injected subcutaneously, may have modulated the immune system.  
 
Nisin F proved an effective antimicrobial agent against S. aureus-related infections in the 
respiratory tract, but not against subcutaneous infections. The outcome of nisin F treatment 
thus depends on the route of administration and site of infection. 
 
 iii 
Opsomming 
 
Multi-antibiotika weerstandbiedende Staphylococcus aureus stamme se weerstand teen 
verskeie antimikrobiese middels hou ‘n groot gevaar in, veral vir persone met ‘n verwronge 
immuniteit. Baie stamme van S. aureus ontwikkel voortdurend weerstand teen nuut-
ontwikkelde antimikrobiese middels soos byvoorbeeld quinupristin-dalfopristin, linezolid en 
daptomycin. Die belangstelling in alternatiewe antimikrobiese middels, onder andere ook 
bakteriosiene (ribosomaal gesintetiseerde antimikrobiese peptiede), is aan die toeneem. 
 
Lactococcus lactis subsp. lactis F10, geïsoleer van ‘n varswater barber, produseer ’n nuwe 
variasie nisien aktief teen kliniese stamme van S. aureus. Die operon wat vir nisien F kodeer 
is gelokaliseerd op ’n plasmied en die DNA-volgorde van die strukturele geen is bepaal. 
Nisien F is die naaste verwant aan nisien Z, behalwe vir die voorkoms van valien in plaas van 
‘n isoleusien op posisie 30.     
 
Die antimikrobiese aktiwiteit van nisien F teen S. aureus is in die respiratoriese lugweë van 
Wistar rotte getoets. Rotte met ‘n gesonde immuunstelsel en rotte met ‘n onderdrukte 
immuunstelsel is intranasaal met S. aureus K geïnfekteer en daarna met nisien F of ‘n steriele 
fisiologiese soutoplossing behandel. Nisien F het immuun-onderdrukte rotte beskerm teen S. 
aureus aangesien simptome van ’n infeksie net in die tragea en longe van immuun-
onderdrukte rotte wat met ‘n soutoplossing behandel is, waargeneem kon word. Die toksisiteit 
van intranasaal geadministreerde nisien F is geëvalueer en geen newe-effekte is waargeneem 
nie. 
 
Die potensiaal van nisien F as ’n antimikrobiese middel om onderhuidse velinfeksies te 
behandel is ondersoek deur C57BL/6 muise met ’n bio-luminiserende stam van S. aureus 
(Xen 36) te infekteer. Immuun-onderdrukte muise is met nisien F of steriele fisiologiese 
soutoplossing behandel 24 en 48 h nadat hulle met S. aureus Xen 36 onder die huid 
geïnfekteer is. Histologie en bioluminiserende fluksie-lesings het getoon dat nisien F 
oneffektief is in die behandeling van diep dermale S. aureus-geassosieerde infeksies. 
Ongeïnfekteerde en geïnfekteerde nisien-behandelde muise het ’n influks van 
polimorfonukleêre selle in die diep stroma van die velweefsel teweeggebring. Nisien F, 
onderhuids ingespuit, mag dalk tot modulering van die immuunstelsel aanleiding gee.  
 
 iv 
Nisin F is effektief teen S. aureus-geassosieerde infeksies in lugweë, maar nie teen 
onderhuidse infeksies nie. Die effektiwiteit van nisin F hang af van die roete van 
adiministrasie en die area van infeksie. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 v 
Preface 
 
The literature study is an overview of Staphylococcus aureus and its association with 
respiratory tract and skin infections. Bacteriocins and their applications in the medical field 
are also discussed with emphasis on in vivo techniques used to study antimicrobial efficiency. 
 
The manuscript “Characterization of the structural gene encoding nisin F, a new lantibiotic 
produced by Lactococcus lactis subsp. lactis isolate from freshwater catfish (Clarias 
gariepinus)” has been published in Applied and Environmental Microbiology (2008; 74:547-
549). 
 
The manuscript “Nisin F in the treatment of respiratory tract infections caused by 
Staphylococcus aureus” has been published in Letters in Applied Microbiology (2009; 48:65-
70).  
 
The chapter “Nisin F in the treatment of subcutaneous skin infections by monitoring 
bioluminescent Staphylococcus aureus non-invasively and in real-time” has been prepared for 
submission to the Journal of Antimicrobial Chemotherapy. 
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 2 
Introduction 
 
Antibiotics, imperative in modern medicine, are at risk of becoming ineffective in combating 
bacterial infections. The increasing occurrence of antibiotic resistance and the lack of newly 
discovered antibiotics are the two major factors responsible. The decreased susceptibility of 
bacteria against antibiotics, and in many cases complete resistance, is a worldwide 
phenomenon that is increasing at an alarming rate. Bacteria resistant to the majority of 
clinically used antibiotics are referred to as “superbugs” and are especially prevalent in 
communities and hospitals, presenting a great threat. Furthermore, no new antibiotic classes 
have been discovered over the last 12 years and only a few new antibiotics have been 
approved as drugs since 1963. “The end of the antibiotic era” emphasizes the importance of 
continuously developing new antimicrobial agents or investigating alternative approaches for 
fighting “superbugs” (Hancock, 2007).  
 
Staphylococcus aureus, a “superbug”, is a Gram-positive organism that belongs to the 
Micrococcaceae family. This organism is an opportunistic pathogen associated with a variety 
of respiratory tract infections, including chronic sinusitis (Brook, 2005), acute otitis media 
(Grzegorowski and Szydlowski, 2005), healthcare-associated pneumonia (Harmanci et al., 
2002) and community-acquired pneumonia (Micek et al., 2007). S. aureus is also associated 
with skin and soft tissue infections (Brook, 2008). Multidrug-resistant strains such as 
methicillin-resistant Staphylococcus aureus (MRSA) cause major health care problems, 
particularly in hospitals and communities. MRSA strains are also resistant to macrolides, 
lincosamides, flouroquinlones, tetracyclines, aminoglycosides and chloramphenicol (Almer et 
al., 2002). Even more alarmingly, S. aureus strains have been isolated that are resistant to 
newly developed antimicrobial agents such as quinupristin-dalfopristin, linezolid, daptomycin 
and tigecycline (Fagon et al., 2000; Peeters and Sarria, 2005; Skiest, 2006).  
 
In South Africa S. aureus, and especially multidrug-resistant S. aureus strains, are a major 
health problem. A study conducted in Cape Town investigated the presence of potential 
bacterial pathogens in 203 HIV-infected children. S. aureus was present in 20.4% of the 
children, of which 77% of the strains were methicillin-resistant (Cotton et al., 2008). S. 
aureus is responsible for serious secondary bacterial infections in HIV-infected individuals as 
illustrated by another study also conducted in Cape Town. S. aureus was found to be the 
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causative agent in 14% of serious bacterial infections in 141 hospitalized HIV-infected 
children. All the strains were methicillin-resistant and were predominantly associated with 
pneumonia (Jaspan et al., 2008).    
 
Lactic acid bacteria (LAB) and the antimicrobial agents they produce have been considered as 
a possible solution to the problem of controlling multidrug-resistant pathogens (Gillor and 
Ghazaryan, 2007; Sleator and Hill, 2008). LAB are either rod or coccoid shaped 
asporogenous cells that grow under micro-aerophylic conditions. Lactic acid is the main end 
product of the strictly fermentative metabolism (Axelsson, 2004). The ribosomally 
synthesized antimicrobial peptides they produce are known as bacteriocins and are small 
cationic proteins with high isoelectric points and amphiphilic characteristics. These proteins 
generally exhibit antimicrobial activity against strains closely related to the producer strains 
(Tagg et al., 1976). 
 
Lantibiotics falls into one of the bacteriocins’ subclasses and are characterized by the 
presence of lanthionine rings and dehydrated residues. Nisin is probably the most widely 
known lantibiotic and is the only bacteriocin approved for commercial use. Nisin is usually 
produced by strains of Lactococcus lactis subsp. lactis. However, nisin U and U2 are 
produced by Streptococcus uberis (Breukink and de Kruijff, 1999; Wirawan et al., 2006). 
Gram-positive bacteria, including foodborne pathogens and clinical strains of the genera 
Bacillus, Clostridium, Listeria and Staphylococcus are usually inhibited (Breukink and de 
Kruijff, 1999). Nisin was originally commercialized for food preservation in products such as 
processed cheese and cheese spreads (Delves-Broughton et al., 1996).  
 
Recently the application of nisin as an antimicrobial in the medical and veterinary fields has 
been investigated. Nisin has successfully been used in the treatment of mastitis, i.e. 
intramammary S. aureus infections, in cows (Cao et al., 2007; Wu et al., 2007).  Mastitis in 
women has also successfully been treated with nisin (Fernández et al., 2008). Nisin has been 
incorporated in topical formulations used for the treatment of S. aureus infections in atopic 
dermatitis, but has only been tested in vitro (Valenta et al., 1996). Research on microbicides 
containing nisin has also been conducted (Aranha et al., 2004; Reddy et al., 2004). Nisin was 
also administered to the nares of cotton rats. The attempted decolonization of S. aureus was 
unsuccessful, probably due to the absorption of nisin in the nasal tract (Kokai-Kun et al., 
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2003). In vivo studies investigating nisin as an alternative to antibiotics are, despite its 
enormous potential, very limited.   
 
The aim of this study was to characterize nisin F and investigate whether this lantibiotic has 
an antimicrobial effect in vivo against S. aureus related respiratory tract and skin infections. 
This is an initial study on the possible medical applications of nisin F.  
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Literature review 
 
2.1. Staphylococcus aureus and its association with respiratory tract and skin infections 
 
Staphylococcus aureus is a pathogen that belongs to the family Micrococcaceae and cells 
form characteristics coccoid Gram-positive clusters. Colonies are gold-coloured and strains 
usually ferment mannitol. S. aureus is highly adaptive and grow as a commensal 
microorganism or as a pathogen in various infections. S. aureus is increasingly associated 
with respiratory tract and skin infections, especially in hospitals and communities. This is due 
to a range of virulence factors and the increasing prevalence of multi-drug resistant S. aureus 
strains, resulting in treatment failure (Lowy, 1998).     
 
The anterior nares of the human and animal nose (Lowy, 1998; Vautor et al., 2005) is the 
most common site for S. aureus infections, followed by the skin, perineum and pharynx 
(Wertheim et al., 2005). S. aureus spreads from the surfaces, were it could survive for 
extensive periods, to the hands of humans. In hospitals methicillin-resistant Staphylococcus 
aureus (MRSA) outbreaks mainly occur when strains are transmitted from hospital personnel 
to patients. MRSA strains also infect the nasal cavity through airborne transmission (Farrell et 
al., 1998; Solberg, 2000). The same strains have been isolated from mothers and their 
children, indicating that transmission also occurs among household members (Peacock et al., 
2003). Nasal carriage of S. aureus has been associated with an increased risk of subsequent 
staphylococcal disease (Chapoutot et al., 1999; Stanaway et al., 2007).  The significance of S. 
aureus nasal carriage remains to be debated, since decolonization of S. aureus from the nasal 
tract to prevent staphylococcal disease has only been successful in individuals that have been 
predisposed to S. aureus infections (Kalmeijer et al., 2002; Wertheim et al., 2004). One study 
revealed that the oropharynx of children suffering from cystic fibrosis, and not the nose, is the 
predominant site of S. aureus infection (Ridder-Schaphorn et al., 2007). 
 
S. aureus is a causative agent in upper respiratory tract infections such as chronic sinusitis 
(Brook, 2005), acute otitis media (Grzegorowski and Szydlowski, 2005), tympanostomy tube 
otorrhea (Francois et al., 2001), chronic suppurative otitis media (Verhoeff et al., 2006) and 
otitis externa (Ramsey, 2002).  Upper respiratory tract infections usually occur in stages, 
starting with a viral infection or allergic inflammation. Complete recovery from infection 
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occurs in the majority of cases after 10 days (Gwaltney et al., 1981).  Facultative aerobic 
bacteria, i.e. Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, and 
S. aureus cause secondary acute bacterial infections in cases where viral infections or 
inflammation were not resolved. Anaerobic bacteria from the oral cavity may predominate 
over time (Brook et al., 1996; Meyers, 1984). 
 
S. aureus is also associated with lower respiratory tract infections such as cystic fibrosis lung 
disease, especially in two to three year-old infants, and pneumonia (Baughman et al., 1999; 
Harmanci et al., 2002; Micek et al., 2007; Saiman, 2004; Stone and Saiman, 2007). Patients 
with cystic fibrosis have a defective cystic fibrosis transport regulator (CFTR) gene resulting 
in inconsistent mucus secretion and malfunctioning of the pancreas (Riordan et al., 1989). 
This in turn leads to colonization of pathogenic bacteria such as S. aureus in the lungs, 
causing inflammation. Chronic inflammation progressively destructs the bronchopulmonary 
tissue which leads to respiratory insufficiency and death (Kilian and Kisiel, 2006).    
 
S. aureus has been associated with hospital-acquired (nosocomial) and community-acquired 
pneumonia (Baughman et al., 1999; Harmanci et al., 2002; Micek et al., 2007). Community-
acquired pneumonia is often more severe since these strains harbour the Panton-Valentine 
leukocidin (PVL) gene (Baldwin and Lowe, 2008; Balis et al., 2007).  The main route of entry 
of S. aureus into the lungs is by micro-aspiration of oropharyngeal secretions. The 
oropharyngeal secretions are usually contaminated by bacteria that colonize the upper 
respiratory tract. After initial colonization with adhesive proteins, discussed later, an infection 
begins with bronchiolitis that may progress to bronchopneumonia. Bronchopneumonia may 
be extended to adjacent regions of the lung, resulting in confluent pneumonia, with or without 
abscess formation (Johanson and Dever, 2003). S. aureus has been isolated from these 
abscesses (Patradoon-Ho and Fitzgerald, 2007). 
 
S. aureus is associated with skin and soft tissue infections (SSTIs) that manifests as cellulitis, 
boils and abscesses. These infections, if not treated and prolonged, lead to osteomyelitis and 
even necrotizing fasciitis. SSTIs usually occur in areas of the body that have been previously 
injured or compromised (Brook, 2008; Miller et al., 2005). Community-acquired methicillin-
resistant S. aureus (CA-MRSA) is more prevalent in SSTIs than hospital-acquired methicillin-
resistant S. aureus (HA-MRSA), 75% compared to 37% (Naimi et al., 2003). 
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One of two things, at least, must occur for an infection to form in a human. Either a highly 
virulent microorganism must be introduced, or the host defenses have to be impaired. Factors 
that can impair a host defense system and predispose an individual to a S. aureus infection are 
listed in Table 1. This is followed by a discussion of a range of virulence factors, i.e. a variety 
of adhesions on the cell surface, production and secretion of tissue damaging toxins, biofilm 
formation, and resistance against antimicrobial peptides and medicaments (Mack et al., 2004; 
Peschel, 2002).  
 
TABLE 1. Factors that predispose humans to S. aureus infections 
Risk factor Reference 
Diabetes mellitus Lipsky et al. (1987) 
Haemodialysis procedures Kirmani et al. (1978) 
Continuous peritoneal dialysis for end stage liver disease Nouwen et al. (2006) 
Cystic fibrosis Ulrich et al. (1998) 
Obesity Herwaldt et al. (2004) 
Human immunodeficiency virus (HIV) infection Sissolak et al. (2002) 
Previous S. aureus skin infections Williams et al. (1998) 
Intubation and prolonged mechanical ventilation Pujol et al. (1998) 
Length of hospitalization or prolonged stay in intensive 
care unit 
Pujol et al. (1998) 
Previous broad-spectrum antibiotic treatment Pujol et al. (1998) 
Atopic dermatitis Benenson et al. (2005) 
Intravenous drug usage González et al. (2003) 
Surgery Homer-Vanniasinkam (2007) 
Trauma Brook (2008) 
Burns Blyth (2008) 
 
S. aureus has to adhere to the epithelial cells of the nasal cavity to colonize and cause 
infection. Strains isolated from nasal carriers harbour genes that encode collagen adhesins 
(cna) and fibronectin-binding proteins (fnbA and fnbB) (Nashev et al., 2004). Endothelial 
cells infected with strains containing fnbA and fnbB release higher levels of interleukin-6, in 
comparison to cells infected with mutants of S. aureus deficient in fnbA and fnbB (Söderquist 
et al., 2006). Genotyping of S. aureus strains isolated from patients suffering from SSTIs 
revealed the presence of adhesion genes map, eap and fnbB (Campbell et al., 2008). S. aureus 
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uses teichoic acid, a surface-exposed polymer, to attach to human epithelial cells 
(Weidenmaier et al., 2004).  Sigma B also plays a role in the early infection of S. aureus 
strains by enhancing the cell’s ability to attach to fibrinogen- or fibronectin-coated surfaces 
(Entenza et al., 2005). Another surface-expressed protein, clumping factor B, enhances 
colonization by adhering to epidermal cytokeratins (O’Brien et al., 2002). S. aureus, in 
addition to these surface-expressed proteins, also secretes proteins that enhance binding to 
various cells such as Map (Kreikemeyer et al., 2002), Eap (Hussain et al., 2001a), Emp 
(Hussain et al., 2001b) or Efb (Bodén and Flock, 1994).  
 
Single chain staphylococcal enterotoxins (SEs) and toxic shock syndrome toxin are important 
virulence factors that knock out specific subsets of T cells of the host’s immune system 
(Fleischer et al., 1991; Poindexter and Schlievert, 1986). S. aureus strains isolated from stable 
nasal carriers harbour genes coding for enterotoxins SEA, SEB, SEC, SED and SEJ, and 
TSST-1 (Fueyo et al., 2005; Nashev et al., 2004). The strains may also harbour the 
enterotoxin gene cluster (egc) that encode enterotoxins SEG, SEI, SEM, SEN, and SEO 
(Bania et al., 2006). Clinical strains isolated from SSTIs harbour genes that encode 
enterotoxins SEA, SEB, SED, SEG, SEJ and SEE (Campbell et al., 2008; Schlievert et al., 
2008), toxic shock syndrome toxin (Lina et al., 1997; Schlievert et al., 2008) and exfoliative 
toxins A and B (Lina et al., 1997). 
 
S. aureus strains producing the PVL toxin have been associated with necrotising pneumonia 
and furunculosis (Lina et al., 1999). Necrotising pneumonia is characterized by abscess 
formation, cavitation, haemorrhage, necrosis and a mortality rate as high as 75% (Gillet et al., 
2002). Furunculosis is a skin lesion associated with a painful inflammatory reaction and 
involves the hair follicle (Brook, 2008). PVL-producing S. aureus attaches itself to exposed 
collagen of damaged epithelial. Rapid bacterial multiplication follows with the secretion of 
cytotoxins, i.e. haemolysins, which causes tissue damage and bacterial spreading (de 
Bentzmann et al., 2004). When the cells reach a high concentration a quorum-sensing system 
accessory gene regulator induces the expression of protease and cytotoxic alpha toxins. 
Leukocidin protects the cells by destroying polymorphs, and is with other necrotising toxins, 
responsible for necrotising vasculitis with massive areas of infarction and haemorrhage 
(Seeger et al., 1990).  
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S. aureus strains are able to form biofilms in the respiratory tract (Amaral et al., 2005; 
Sanderson et al., 2006) and on the skin of humans (Smith et al., 2008). The first step in 
biofilm formation is attachment of the cells to biomaterial such as mucus. The mature biofilm 
is established after the bacteria have formed multiple layers and glycocalyx. The phenotypic 
characteristics of cells in biofilms are altered with respect to bacterial physiology, metabolism 
and gene transcription (Donlan and Costerton, 2002; Yarwood et al., 2007). Such biofilms 
complicate therapeutic treatment because of acquired resistance to a variety of antimicrobials 
and the host’s immune system (Mack et al., 2004).  
 
S. aureus is resistant to defensins, cathelicidins and thrombocidins, collectively known as 
cationic antimicrobial proteins (CAMPs). These compounds may play an important part in the 
innate immune system, as they form the first line of defense during bacterial colonization and 
infection (Jin et al., 2004; Medzhitov and Janeway, 2000). CAMPs have cationic properties to 
target anionic microbial substances and so limit damage to host cells (Fedtke et al., 2004). 
MprF encodes resistance against defensins by modifying the membrane lipids with l-lysine 
(Peschel et al., 2001). The dlt operon also builds resistance against CAMPs by the 
incorporation of D-alanine into S. aureus teichoic acids. Teichoic acids are major components 
of the S. aureus cell wall (Peschel et al., 1999). Both these modifications decrease the 
negative surface charge of the cell walls of bacterial cells and in turn fewer CAMPs bind to S. 
aureus cells. Another important CAMP that S. aureus is resistant to is lysozyme. The gene 
responsible for lysozyme resistance is the peptidoglycan O-acetyltransferase OatA (Bera et 
al., 2005). S. aureus also produces the exoprotein staphylokinase that forms a complex with 
alpha-defensins, rendering them ineffective (Jin et al., 2004). Braff et al. (2007) hypothesized 
that staphylokinase uses cathelicidins to promote fibrinolysis and enhance bacterial 
dissemination, hence invasive infection. 
 
The majority of antibiotics available in the pharmaceutical industry today originated from 
natural templates certain species of microorganisms produced to render them a natural 
competitive advantage. Antibiotic resistance developed in other microorganisms for survival 
against these toxic chemicals. Microorganisms become resistant either by mutations or by 
exchanging genetic resistance determinants with other microorganisms (Hancock, 2005). This 
is clearly illustrated with S. aureus which continuously acquires resistance to newly 
developed antibiotics.    
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Methicillin, a semi-synthetic penicillin, was developed to overcome the problem of penicillin-
resistant S. aureus strains. Methicillin was only efficient for a short period of time with 
resistant strains detected soon after the antibiotic was introduced (Ayliffe, 1997). The spread 
of MRSA strains increased rapidly worldwide. As in the case of British bacteraemia patients, 
2% of S. aureus strains were methicillin-resistant in the early 1990s. This increased to 43% 
between 1997 and 2002 (Johnson et al., 2005). Methicillin resistance amongst S. aureus 
strains occurs mainly in hospitals and communities and is labeled as hospital-acquired 
methicillin-resistant S. aureus (HA-MRSA) and community-acquired methicillin-resistant S. 
aureus (CA-MRSA). HA-MRSA and CA-MRSA differ genetically, in their antibiotic 
susceptibility profiles and their spectrum of associated infection (Moellering et al., 2007).   
 
Glycopeptides, i.e. vancomycin and teicoplanin, are used as standard treatment for S. aureus 
infections. Vancomycin is the first choice of treatment, especially when dealing with MRSA 
infections. Alternative antibiotics such as rifampicin, tetracyclines and fusidic acid are also 
used, depending on the infection site and the susceptibility profile of the microorganism 
(Casey et al., 2007).   
 
Vancomycin, like other glycopeptides, inhibits the biosynthesis of peptidoglycan in bacterial 
cell walls (Groves et al., 1994). The occurrence of MRSA strains with reduced susceptibility 
towards vancomycin is on the rise (Howden, 2005; Ruef, 2004). Vancomycin-sensitive 
MRSA strains were found to be less susceptible to vancomycin after persistent infection. This 
reduced susceptibility is associated with a thickening of the cell wall, reduced autolytic 
activity and a reduction in biofilm-forming ability (Howden et al., 2006). Even more 
alarming, is the isolation of seven S. aureus strains resistant to vancomycin, all from USA 
(Appelbaum, 2006; Chang et al., 2003). The transfer of plasmids containing the vanA gene 
cluster from vancomycin-resistant enterococci is responsible for resistance in the seven S. 
aureus strains (Weigel et al., 2007).     
 
The decreased susceptibility of S. aureus strains to glycopeptides and methicillin has led to 
the development and registration of the new antistaphylococcal agents; quinupristin-
dalfopristin, linezolid, daptomycin and tigecycline. Quinupristin and dalfopristin are two 
semisynthetic streptogramin derivates that acts synergistically against MSSA and MRSA 
when combined in a 30:70 (w/w) ratio (Ling et al., 2001). Quinupristin-dalfopristin inhibits 
protein synthesis by binding onto the bacterial 50S ribosomal subunit. Dalfopristin binds 
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initially to the ribosome peptidyl site which enhances subsequent binding of quinupristin to a 
separate but overlapping site (Johnston et al., 2002; Vannuffel and Cocito, 1996). Resistance 
to quinupristin-dalfopristin is low due to the synergistic action of the two structurally 
unrelated compounds. Quinupristin resistance is mediated by 23S rRNA target methylation by 
members of the erythromycin resistance methylase gene (erm) class and by linearization of 
the hexadepsipeptide ring by a specific plasmid-mediated lyase (Klastersky, 2003; Thal and 
Zervos, 1999). Dalfopristin resistance is mediated by plasmid-mediated acetyltransferases that 
utilize acetyl-coenzyme A to enzymatically inactivate the compound (Kehoe et al., 2003). 
Recently S. aureus strains resistant and less susceptible to quinupristin-dalfopristin have been 
isolated (Despande et al., 2004; Hsueh et al., 2005). 
 
Linezolid, an oxazolidinone, is bacteriostatic against MSSA and MRSA. Linezolid binds to 
the 23S ribosomal RNA of the 50S ribosomal subunit, blocking the formation of the 
ribosomal initiation complex and hence protein synthesis. Cross resistance between linezolid 
and other protein inhibitors, i.e. chloramphenicol, is infrequent because of linezolid’s unique 
mechanism of action (Diekema and Jones, 2001). Rare cases of acquired resistance have been 
found in clinical S. aureus strains, isolated from patients with indwelling prosthetic devices 
(Gonzales et al., 2001; Kola et al., 2007). Point mutations in domain V of the 23 rRNA of the 
50S ribosomal subunit are responsible for this acquired resistance (Gonzales et al., 2001).   
 
Daptomycin, a cyclic peptide antimicrobial, is bactericidal against MSSA and MRSA. 
Daptomycin inserts itself into the cell membrane of sensitive cells causing the membrane to 
depolarize and to release its potassium ions. This in turn results in the inhibition of DNA, 
RNA, and protein synthesis (Silverman et al., 2003).  S. aureus strains resistant to daptomycin 
are extremely rare (Hayden et al., 2005; Mangili et al., 2005; Marty et al., 2006).  
 
Tigecycline is a glycylcycline antibiotic with a fused tetracycline, minocylnine structure and 
is modified by the addition of a 9-t-butylglycylamido side chain (Doan et al., 2006). 
Tigecyclines binds to the 30S ribosomal subunit, blocking the addition of amino acids to 
polypeptide chains and hence inhibit protein synthesis. Tigecycline is a broad-spectrum 
antibiotic with bacteriostatic activity against MSSA and MRSA (Fritsche et al., 2005). 
 
The isolation of S. aureus strains resistant to the newly registered antistaphylococcal agents, 
although rare, is still a concern. This drives the need for the continuous exploration of new 
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antimicrobial agents, of which the following drugs are in the advanced stages of clinical 
testing. Dalbavacin, oritavacin and telavancin are second-generation glycopeptides with a 
prolonged half-live, active against MRSA strains (Jábes et al., 2004; Stryjewski et al., 2005; 
Van Bambeke, 2006). Ramoplanin, a lipoglycodepsipeptide, is another newly developed 
antibiotic with activity against multi-drug resistant S. aureus strains. Ramoplanin interferes 
with the biosynthesis and transglycosylation of lipid II in the cell wall of bacterial cells (Hu et 
al., 2003; Somner and Reynolds, 1990). Other examples are ceftobiprole, ceftaroline, 
iclaprim, CS-023/RO-4908463, and adjuvant therapies, i.e. monoclonal antibody tefibazumab 
(Pan et al., 2008). 
 
2.2. Bacteriocins with emphasis on nisin 
 
Bacteriocins are gene-encoded peptides that exhibit antimicrobial properties against other 
bacterial species that are usually closely related to the producer strain. Lactic acid bacteria 
(LAB) are well known for their production of bacteriocins. These Gram-positive, nonsporing, 
nonrespiring cocci or rods follow a strictly fermentative metabolism with lactic acid as end 
product (Axelsson, 2004). Bacteriocins produced by LAB are small cationic proteins with 
high iso-electric points and amphiphilic characteristics (Tagg et al., 1976). Klaenhammer 
(1993) originally classified bacteriocins into four distinct classes, based on their biochemical 
and genetic characteristics, structures and mechanisms of action. Recently, Cotter et al. 
(2005a) reclassified bacteriocins into two groups i.e. Class I, lantibiotics and Class II, 
nonlantibiotics (Table 2).  
 
 
TABLE 2. Classification of bacteriocins (Cotter et al., 2005a) 
Class  Characteristics Example Reference 
Class I Small (< 5 kDa), heat stable posttranslationally 
modified peptides containing lanthionine and 
methyllanthionine amino acids  
 Chatterjee et 
al. (2005); Jack 
and Sahl 
(1995) 
Class Ia Elongated, flexible positively charged peptides. 
Forms pores in cytoplasmic membranes of 
sensitive cells 
nisin Breukink and 
de Kruijff 
(1999) 
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Class  Characteristics Example Reference 
Class Ib 
  
Globular, rigid peptides with a negative or no 
net charge. Interfere with essential enzymatic 
reactions of sensitive cells 
mersacidin Bierbaum et al. 
(1995)  
Class II  Small (< 10 kDa) heat stable nonlanthionine 
containing peptides  
  
Class IIa Pediocin-like peptides with conserved 
YGNGVXCXXXXXCXV region in N-
terminal domain 
pediocin 
AcH/PA-1 
Eijsink et al. 
(1998) 
Class IIb Two-component bacteriocins requiring two 
peptides for activity  
lactococcin G Nissen-Meyer 
et al. (1992) 
 
Nisin is a small, ribosomally synthesized, antimicrobial peptide produced by certain 
Lactococcus lactis strains. The exception is nisin U that is produced by Streptococcus uberis 
(Breukink and de Kruijff, 1999; Wirawan et al., 2006). Lactococcus lactis and Streptococcus 
uberis are LAB that previously formed part of the genus Streptococcus. This genus has since 
been divided into three separate taxons, namely Enterococcus, Lactococcus and Streptococcus 
sensu stricto (Schleifer, 1987).  
 
Mattick and Hirsch (1947) discovered the first lantibiotic, nisin A, but the structure was only 
published a few years later by Gross and Morell (1971). Since then, many lantibiotics have 
been discovered, among them five other natural variants of nisin Z, Q, F, U and U2. Nisin A, 
Z, Q and F have similar activities, but differ only in a few amino acids. Nisin A and nisin Z 
differ only in a single amino acid and nisin A from nisin Q in six amino acids (Buchman et 
al., 1988; Mulders et al., 1991; Zendo et al., 2003). Nisin A differs from nisin F in two amino 
acids and nisin F differs from nisin Q in four amino acids (de Kwaadsteniet et al., 2008).  
Nisin U is only 78% identical to nisin A and Z and 82% identical to nisin Q (Wirawan et al., 
2006).  
 
Nisin has antimicrobial activity against various Gram-positive bacteria, including Bacillus, 
Clostridium, Listeria and Staphylococcus spp. (Breukink and de Kruijff, 1999). This peptide 
is part of the lantibiotic family because of the lanthionine rings and dehydrated residues in its 
structure (Buchman et al., 1988). Lantibiotics are divided into two groups as mentioned 
earlier, the elongated type A group and the globular type B group with nisin falling into the 
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first group (Table 2). Nisin is a cationic peptide with amphipathic properties. The dehydrated 
residues are formed posttranslational when serine and threonine are dehydrated to respectively 
dehydroalanine (Dha) and dehydrobutyrine (Dhb). The lanthionine rings are then formed 
when five of the dehydrated residues are coupled to upstream cysteines. These cysteines are 
then converted to alanine and the S used to form the thioether bonds (Fig. 3).  These thioether 
bonds form a N-terminally and a C-terminally ring system that is separated by a hinge region 
(residues 20 - 22). Nisin is now positioned in a screw-like structure that is responsible for its 
amphipathic characteristics (Fig. 3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1. The primary structure of nisin A. The lanthionine rings (A-S-A, lanthionine; Abu-S-
Ala, methyllanthionine) and the dehydrated residues (Dhb, dehydroalanine; Dha, 
dehydrobutyrine) are respectively coloured in green and blue (Breukink and de Kruijff, 1999).  
 
The nisin A operon has been studied in detail.  The nisin gene cluster consists out of 11 genes, 
i.e. nisA, nisB, nisT, nisC, nisI, nisP, nisR, nisK, nisF, nisE and nisG (Fig. 4).  This gene 
cluster is situated on a conjugative plasmid, together with sacA encoding sucrose-6-phosphate 
hydrolase (Rauch and de Vos, 1992). Transposons that vary slightly form strain-to-strain 
flank the operon and the sacA gene. These transposons are transferred to enterococci through 
conjugation (Broadbent et al., 1995). The structural gene nisA encodes the prepeptide 
(Buchman et al., 1988).  NisB and nisC are involved in maturation of the lantibiotic and nisT 
in transport across the cell membrane (Engelke et al., 1992).  NisI encodes an immunity 
A 
A L G 
K I 
I 
I 
A A 
A 
A 
A 
L 
P G 
G 
K 
K 
M 
M N H A S 
H 
V 
Dhb 
Dha 
Dha 
Ab Ab Ab
Ab
S S S 
S 
S 
1 12 20 22 27 
34 
 18 
protein and nisP a putative serine protease involved in processing (Engelke et al., 1994).  
NisR and nisK encode a regulatory protein and a histidine kinase (Engelke et al., 1994).  NisF, 
nisE and nisG encode ATP-binding cassette (ABC) transporters that play a role in immunity 
together with nisI (Siegers and Entian, 1995; Stein et al., 2003). 
 
 
 
 
 
Fig. 2. The nisin gene cluster consisting out of eleven genes (blue arrows) namely nisA, nisB, 
nisT, nisC, nisI, nisP, nisR, nisK, nisF, nisE and nisG (Engelke et al., 1994; Stein et al., 
2003). 
 
The mode of action is the formation of voltage-dependent pores in the plasmamembrane of 
target cells, which allows the efflux of potassium ions, ATP and amino acids. The membrane-
bound cell wall precursor lipid II plays an important role in the pore formation since it acts as 
nisin’s docking molecule (van Heusden et al., 2002).  Nisin bounded to lipid II further 
increases its effectiveness as an antimicrobial by inhibiting bacterial cell wall synthesis 
(Wiedemann et al., 2001).  
 
Klaenhammer (1993) defined three categories of nisin resistance for Gram-positive bacteria. 
Firstly, nisin-producing strains are protected from its own bacteriocin with the immunity 
genes nisI and nisFEG (Engelke et al., 1994; Siegers and Entian, 1995). Secondly, nisinases 
(nisin-inactivating enzymes) have been isolated from non-nisin-producing Gram-positive 
strains (Jarvis and Farr, 1971). Lastly, is the acquirement of nisin resistance. A variety of 
different mechanisms have been observed among Gram-positive sensitive strains that 
acquired nisin resistance. Nisin resistance in Listeria strains coincided with a thickening in the 
cell wall (Maisnier-Patin and Richard, 1996) and changes in the fatty acid composition of the 
cell membrane (Mazzotta and Montville, 1997). Lipoteichoic acids in the cell walls of S. 
aureus and Streptococcus bovis are associated with nisin-resistance (Mantovani and Russell, 
2001; Peschel et al., 1999). A putative binding protein is also associated with nisin-resistance 
in L. monocytogenes strains (Gravesen et al., 2001). The complexity by which sensitive 
Gram-positive bacteria acquire nisin resistance was studied by Kramer et al. (2006). 
Transcriptional analysis revealed that 92 genes in L. lactis IL1403 are either directly or 
A B T C I P R K F E G 
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indirectly involved in acquired nisin resistance.  The following four mechanisms are involved: 
(i) preventing nisin from reaching the cytoplasmic membrane and lipid II molecule; (ii) 
stimulating the binding of nisin to the cell wall by increasing the pH of the extracellular 
medium which promotes degradation and immobilization; (iii) preventing nisin insertion into 
the membrane and (iv) ATP-transporters may possibly be involved in the extrusion of nisin 
from the cytoplasmic membrane. Bacteria may use more than one mechanism simultaneously 
to protect themselves against nisin (Kramer et al., 2006).  
 
Nisin has generally regarded as safe (GRAS) status and inhibit food borne pathogens (Delves-
Broughton et al., 1996; Rilla et al., 2004). Numerous toxicology studies proved that nisin has 
a low toxicity (Fowler, 1973; Lloyd and Drake, 1975). The American Food and Drug 
Administration (Federal Register, 1988) and a joint commission of the Food and Agriculture 
Organization and World Health Organization (WHO, 1969) have approved nisin A for certain 
applications in food. Nisin inhibits spore outgrowth (Chan et al., 1996) and is mainly used to 
protect processed cheese and cheese spreads from contamination (Delves-Broughton et al., 
1996).  
 
2.3. The application of bacteriocins in the medical field  
 
Bacteriocins and bacteriocin-producing LAB are being intensively studied since their 
antimicrobial activity against pathogens render them as possible alternatives to antibiotics. 
Clostridium difficile is a common cause of hospital-acquired diarrhoea associated with a high 
mortality (Pépin et al., 2005). Lacticin 3147 (Rea et al., 2007) and nisin (Bartoloni et al., 
2007) have been shown to be antimicrobial against clinical C. difficile strains. Lantibiotics 
such as lacticins (Kim et al., 2003) and nisin (Morency et al., 2001) also inhibit Helicobacter 
pylori, a gastric pathogen contributing to gastroduodenal ulcers and gastric adenocarcinoma 
(Kandulski et al., 2008).  The spent culture supernatants of two Lactobacillus acidophilus 
strains, LB and La1, were shown to protect mice against Helicobacter felis (Coconnier et al., 
1998) and humans against H. pylori infection (Gotteland et al., 2008; Gotteland and Cruchet, 
2003). Enterocin CR35, produced by E. faecium CRL35, is antimicrobial against herpes 
simplex virus (HSV) (Wachsmans et al., 1999) and inhibits the replication of the virus in vitro 
(Wachsmans et al., 2003). Nisin has been shown to be antimicrobial towards S. aureus (Wang 
et al., 2005). Even MRSA strains have shown a loss in viability after treatment with nisin 
alone (Brumfitt et al., 2002; Severina et al., 1998) and nisin combined with ramoplanin 
 20 
(Brumfitt et al., 2002). Other bacteriocins have also been shown to have antimicrobial activity 
against S. aureus strains in vitro (Table 3).  
 
TABLE 3. Bacteriocins produced by LAB active against S. aureus strains in vitro 
Bacteriocin Reference 
Lactococcus sp.  
Nisin Brumfitt et al. (2002) 
Lacticin 3147 Galvin et al. (1999) 
Diacetin B Ali et al. (1995) 
Lactobacillus sp.  
Plantaricin ST31 Todorov et al. (1999) 
Plantaricin TF711 Hernández et al. (2005) 
Plantaricin 149 Müller et al. (2007) 
Bacteriocin 217 Lozo et al. (2004) 
Bacteriocin LS1 Busarcevic et al. (2008) 
Salivacin 140 Arihara et al. (1996) 
Reutericyclin Gänzle et al. (2000) 
Pediococcus sp.   
Pediocin A Piva and Headon (1994) 
Pediocin AcH Bhunia et al. (1988) 
Leuconostoc sp.  
Mesentericin ST99 Todorov and Dicks (2004) 
Enterococcus sp.  
Enterocin EJ97 Gálvez et al. (1998) 
Enterocin CCM 4231 Lauková et al. (2001) 
Enterocin AS-48 Ananou et al. (2004) 
Enterocin E-760 Line et al. (2008) 
Enterocin P Cintas et al. (1997) 
Carnobacterium sp.  
Carnocin H Blom et al. (2001) 
 
Despite the enormous therapeutic potential of bacteriocins, the numbers of in vivo studies in 
murine models are limited. Kruszewska et al. (2004) investigated the effect of mersacidin on 
S. aureus in a mouse rhinitis model. Mersacidin, a lantibiotic produced by Bacillus sp. HIL Y-
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85, 54728, inhibits the growth of S. aureus in vitro (Bierbaum et al., 1995). The immune 
system of the mice was compromised by hydrocortisone administration before the nasal tract 
was infected with MRSA. S. aureus was not detected in the nasal scrapings of mersacidin-
treated mice, indicating that mersacidin administered intranasally was successful in 
eradicating the infection. Furthermore, only mice not treated with mersacidin had detectable 
levels of interleukin-1 in their blood. The absence of this immune reaction in treated mice 
supports the therapeutical potential of mersacidin (Kruszewska et al., 2004).  Nisin applied in 
the nasal tract of cotton rats was not able to eradicate or decrease S. aureus carriage. The same 
concentration nisin exhibited antistaphylococcal activity in vitro, suggesting that nisin is 
either inactivated or absorbed in the nasal tract (Kokai-Kun et al., 2003).  
 
Nisin has been incorporated in topical formulations used in the treatment of S. aureus 
infections in atopic dermatitis (Valenta et al., 1996). The use of nisin as a safe vaginal 
contraceptive has also been investigated (Aranha et al., 2004; Reddy et al., 2004). Lacticin 
3147 and subtilosin A have also been marked as potential spermicidal candidates (Silkin et 
al., 2008). Mastitis in women and cows have been successfully treated with nisin (Cao et al., 
2007; Fernández et al., 2008; Wu et al., 2007) and lacticin 3147 (Crispie et al., 2005; Ryan et 
al., 1999). Nisin preparations commercially available to treat bovine mastitis include Consept 
(Applied Microbiology, Inc., New York) and Wipe-Out (ImmuCell, Portland, Oregon) (Cotter 
et al., 2005b). The combination of nisin and RNAIII-inhibiting peptide was shown to inhibit 
S. epidermis infection on implanted grafts in Wistar rats (Ghiselli et al., 2004). 
 
Bacteriocins such as nisin and lacticin 3147 are degraded in the intestinal tract and can 
therefore not be taken orally (Bernbom et al., 2006; Gardiner et al., 2007). This hurdle can be 
overcome by the development of “designer probiotics”. Hill and Sleator proposed the cloning 
and expression of bacteriocin genes in a probiotic carrier such as Lactobacillus salivarius, 
enhancing its clinical efficacy (Hill and Sleator, 2008). The alternative is oral administration 
of bacteriocin-producing strains, although they are not of intestinal origin or known 
probiotics. Lacticin 3147- producing L. lactis and nisin-producing L. lactis strains were 
shown to survive intestinal transit in animal models (Bernbom et al., 2008; Dobson et al., 
2008). Nisin has also been incorporated in tablets using pectin/HPMC polymer mixtures and 
was shown to remain active for six hours in vitro, approximately the colon transit time 
(Ugurlu et al., 2007). The importance of bacteriocin production in probiotic strains is 
illustrated by a groundbreaking study by Corr et al. (2007). Lactobacillus salivarius UCC118 
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producing the bacteriocin Abp118 protected mice against Listeria monocytogenes infection. A 
mutant non-bacteriocin producing L. salivarius UCC118 strain failed to protect mice. Also, L. 
salivarius UC118 was ineffective against a mutant L. monocytogenes strain that was able to 
produce the Abp118 immunity protein.  
 
2.4. Molecular imaging 
 
Molecular imaging monitors gene expression in vivo at cellular and molecular levels, using 
imaging detectors that target either endogenous or exogenous genes.  Optical imaging, 
radionuclide-based imaging methods (i.e. positron emission tomography and single photon 
emission computerised tomography) and magnetic resonance imaging (MRI) are all non-
invasive imaging techniques used to study host-pathogen interactions.  
 
Newly developed technology enables light produced by biochemical reactions and biological 
processes in small animals to be detected and quantified. Experimental lay-outs using optical 
imaging in vivo are approached by either using: endogenous fluorochromes; reporter genes 
that generate light internally from specific sources (either bioluminescence of fluorescent 
proteins); or injected contrast agents that incorporate visible light fluorophores, near-infrared 
fluorophores or activated fluorophores (Contag and Ross, 2002). Table 4 lists the advantages 
and disadvantages of using bioluminescence, fluorescent proteins and targeted fluorescent 
probes in optical imaging.    
   
 
 
 
TABLE 4: Comparing the three optical methods used for studying host-pathogen interactions 
 Advantages Disadvantages References 
Biolumine-
scence 
Low signal to noise ratio 
Detects infection recovery  
Closely imitates natural 
bacterial strains 
Suitable for longitudinal 
studies 
Limited tissue penetration of 
visible luminescence 
Availability of oxygen and ATP 
Bacteria must be encoded with 
genetic reporter 
Signal can vary 
Doyle et al. 
(2004) 
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 Advantages Disadvantages References 
Fluorescent 
proteins 
No substrate needed 
Closely imitates natural 
bacterial strains 
Suitable for longitudinal 
studies 
Limited tissue penetration of 
visible emission 
Autofluorescence  
Bacteria must be encoded with 
genetic reporter 
Shaner et 
al. (2005) 
Targeted 
fluorescent 
probes 
Bright near-infrared probes 
developed 
Multimodel probes under 
development 
Enzymes can serve as 
activators 
Probe preparation 
Probe may affect bacterial 
function 
Toxicity and stability of probes  
Not suited for longitudinal 
studies 
Leevy et al. 
(2006) 
 
Positron emission tomography (PET) entails the labeling of a molecule with positron-emitting 
radionuclides and then administrating these labeled molecules by intravenous injection or 
inhalation. Radionuclides decay by emitting positrons and their tissue concentration is 
determined with an imaging device, a PET scanner (Piwnica-Worms et al., 2004). PET 
imaging have for example been applied in studies investigating inflammatory responses to 
infectious organisms (Jones et al., 1997; Schuster et al., 2003). Bacteria or cells can also be 
directly monitored in living animals if they have been modified to express, for example, 
herpes simplex virus type-1 thymidine kinase (HSV1-TK) that is detected through 
radiolabeled ATP analogs (Bettegowda et al., 2005). 
 
Magnetic resonance imaging (MRI) entails that protons within an animal host will absorb 
energy when laying in a magnetic field subjected to a radiofrequency pulse that is applied at 
the correct (resonance) frequency. A detectable signal is then generated when the 
radiofrequency pulse is turned off and the protons emit that energy back into the environment. 
The majority of MRI experiments involve the measurement of protons in water (Piwnica-
Worms et al., 2004). MRI can be used to study pathological tissues in small animals such as 
oedema and inflammation in lungs (Beckman et al., 2001), airway calibre after chronic 
infection with pathogens, and functional assessment of ventilation and perfusion (Piwnica-
Worms et al., 2004). Table 5 lists the advantages and disadvantages of the three molecular 
techniques.  
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TABLE 5: Different molecular imaging techniques for studying host-pathogen interactions 
 Advantages Disadvantages References 
Optical 
imaging 
Low in cost 
Highly versatile 
Enables multichannel imaging 
Simple to execute 
Short image acquisition times  
Simultaneous imaging of more 
than one animal 
Transmission of light through 
animals wavelength 
dependent 
Tissue attenuation 
Lacks depth information 
Low resolution 
Piwnica-
Worms et 
al. (2004) 
Positron 
emission 
tomography 
(PET) 
Tomographic imaging 
capabilities 
Expensive 
Radionuclides are hazardous 
Low sensitivity 
Low resolution 
Doyle et al. 
(2004); 
Contag and 
Ross 
(2002) 
Magnetic 
resonance 
imaging  
High spatial resolution 
Three dimensional imaging 
Expensive 
Difficult to execute 
 
Enninga et 
al. (2007) 
 
Although optical imaging has its disadvantages, it is the best molecular imaging technique to 
use when studying the course of a bacterial infection. PET uses dangerous radionuclides to 
label bacteria and MRI detects the pathological tissues and not the bacteria.  
 
2.5. Bioluminescent imaging studies (BLI)  
 
Bioluminescence imaging (BLI) is a newly developed methodology that uses the light emitted 
from living organisms as a tool for molecular imaging in small laboratory animals.  BLI 
makes the real time, noninvasive in vivo monitoring of infectious diseases possible. In vivo 
BLI works on the following principle. Cells that express light-producing enzymes, luciferases, 
are placed within the host animal. In the presence of ATP and oxygen this enzyme emits 
detectable photons (Doyle et al., 2004; Shah and Weissleder, 2005). BLI systems can capture 
and analyze both bioluminescence and fluorescence using a specialized charge coupled device 
(CCD) camera. After capturing the photons the CCD camera converts them into electrons. 
The CCD camera generates an image by encoding the electrons into electrical charge patterns. 
Background noise is minimized by super-cooling the CCD camera to -90°C and mounting the 
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camera in a light-tight box (Sadikot and Blackwell, 2005). Bioluminescence can be detected 
from genetically engineered microorganisms, cell lines or reporter genes. 
 
There are numerous advantages when using BLI over conventional methods in investigating 
infectious diseases in small animals. The number of animals needed to obtain statistically 
meaningful results is drastically reduced when compared to conventional technologies. This is 
because spatial and temporal data can be collected from the same animal over multiple time 
points without the need of euthanization. The animal models are more accurate since the data 
are collected from intact, living animals (Hutchens and Luker, 2007). Problems associated 
with conventional technologies, such as plate contamination or antibiotics carryover effect, 
that can influence the experimental outcome are also eliminated (Kadurugamuwa et al., 
2003b).  
    
Three luciferase enzymes have to date been characterized and applied for in vivo BLI studies 
in living animals, namely luciferase from fireflies (coleoptara) (de Wet et al., 1985), jellyfish 
and sea pansies (cnidaria) (Hart et al., 1979; Lorenz et al., 1991), and bacteria (Frackman et 
al., 1990). This review will focus on bacterial luciferases and their applications in studying 
Gram-positive bacterial infections. Five essential genes are responsible for the ability of 
bioluminescent bacteria to synthesize light. These genes are organized in an operon such as 
luxCDABE.  Additional lux genes have been identified from bioluminescent bacteria but only 
luxCDABE is responsible for the biosynthesis of light. LuxAB encodes a heterodimeric 
luciferase that catalyses the oxidation of reduced flavin mononucleotide (FMNH2) and a long-
chain fatty aldehyde. This results in blue-green light that is emitted with a peak at 490 nm. 
LuxCDE encodes a fatty acid reductase complex that synthesizes the long-chain fatty 
aldehydes (Meighen, 1993). 
 
Photorhabdus luminescence is ideally situated for BLI studies in mammalian animal models 
since the luciferase it produces has a high thermal stability being stable at even 45°C 
(Meighen, 1993; Szittner and Meighen, 1990). P. luminescence belongs to the terrestrial 
genera Photorhabdus and is like all the other luciferase-producing bacteria Gram-negative 
(Meighen, 1994). The other luciferase-producing bacteria are from marine habitats and belong 
to the genera Vibrio, Photobacterium, and Shewanella (Ulitzur, 1997). The luxCDABE has 
been successfully cloned into Gram-negative bacteria such as Salmonella and Escherichia 
coli (Contag et al., 1995; Xi et al., 1991). Ribosomes in Gram-positive bacteria cannot bind 
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and translate to mRNA from the P. luminescens luxCDABE operon.  This makes the 
translation of the P. luminescens luxCDABE operon into Gram-positive bacteria such as S. 
aureus problematic. The partial lux operon (luxAB) was initially transformed into S. aureus 
with some degree of success (Corbisier et al., 1993). The fact that additional exogenous 
substrate and detergent are required and that the luciferase is unstable above 30°C, makes this 
approach not optimal for the use in animal models (Hill et al., 1993).   
 
Francis et al. (2000) modified the luxCDABE operon so that it could be expressed by Gram-
positive bacteria and was renamed luxABCDE. This was accomplished by inserting a Gram-
positive ribosome binding site (RBS) upstream of each gene and preceding the operon with an 
appropriate promoter sequence. Several highly bioluminescent strains of S. aureus and other 
Gram-positive bacteria were generated after successful transformation with the plasmid. The 
technical disadvantages are that plasmid loss will occur in long term studies due to the 
absence of antibiotics and that plasmid artifacts, such as copy number and supercoiling, which 
will make monitoring unreliable will occur (Francis et al., 2000). The same research group 
overcame the problem by constructing a novel Gram-positive lux transposon cassette, Tn4001 
luxABCDE KmR, which allows the integration of this operon into the chromosome of Gram-
positive bacteria. The luxABCDE and kanamycin genes were linked to a single promoterless 
operon (Fig. 5). This design will result in bioluminescence and kanamycin resistance 
occurring only in a bacterial cell if the operon has transposed downstream of a promoter on 
the genome (Francis et al., 2001). 
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Fig. 3. Plasmid pAUL-A Tn4001 luxABCDE KmR. IR, inverted repeat; EmR, erythromycin 
resistance gene; tnp, transposase gene; TT, transcription terminator (Francis et al., 2001).  
 
Bioluminescence flux measurements of bioluminescent-engineered bacteria correlate well 
with viable cell numbers (Francis et al., 2001; Francis et al., 2000; Hamblin et al., 2003; 
Jawhara and Mordon, 2004; Kadurugamuwa et al., 2003a; Mortin et al., 2007; Rocchetta et 
al., 2001). Certain studies have shown that once microorganisms reach stationary phase, 
viable bioluminescence and viable cell numbers do not correlate anymore (Kadurugamuwa et 
al., 2003b; Kuklin et al., 2003). Discrepancies were also observed between viable cell 
numbers and bioluminescence during a Pseudomonas aeruginosa biofilm study (Marques et 
al., 2005). In both these cases this can be ascribed to the fact that bioluminescence is an 
indicator of the metabolic state of a cell since luciferases are energy-requiring oxygenase 
(Kadurugamuwa et al., 2003b; Marques et al., 2005). Bioluminescence can be detected for 
days and can even reappear after initial diminishing. This is clearly illustrated by a study 
performed by Kadurugamuwa et al. (2003b). Treating biofilm infections on catheters with 
different antibiotics were investigated using bioluminescent S. aureus. Although a 90% 
reduction was observed in the rifampin-treated group the intensity of bioluminescence 
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increased after final treatment.  This makes bioluminescent imaging studies (BLI) ideally 
situated to monitor not only the course of an antimicrobial treatment but also the relapse of 
the treatment (Fig. 4).  
 
 
Fig. 4.  Bioluminescent S. aureus Xen 29 formed biofilms on implanted catheters. The effect 
of antibiotics on the infections was monitored in real-time by measuring the bioluminscence 
(photons/sec/cm2, number of photons per second per square centimeter of catheter) 
(Kadurugamuwa et al., 2003b). 
 
Bioluminescent reporters have a lower signal to noise ratio compared to fluorescent proteins. 
This is because the wavelength used to excite fluorescent proteins causes the mammalian 
tissue to autofluorescence. Mice do not bioluminescence and create a very low signal to noise 
ratio. There are limiting factors to consider when planning and performing BLI studies. The 
detection of bioluminescent bacteria is dependent on the wavelength transmission of light 
through animal tissues. With each centimeter of tissues depth, an approximately 10-fold loss 
of photon intensity is observed.  Another factor to consider, especially in longitudinal studies, 
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is the availability of oxygen and ATP luciferase needs to oxidize reduced flavin 
mononucleotide (FMNH2), as mentioned earlier (Sadikot and Blackwell, 2005). Table 6 lists 
the in vivo studies that used BLI to investigate infectious diseases caused by Gram-positive 
bacteria.  
 
TABLE 6. In vivo studies that investigated Gram-positive bacterial infections using BLI 
Pathogen Aim of study Reference 
S. aureus Investigating the effectiveness of antibiotics in 
treating infections in the thigh muscles of mice 
Francis et al. (2000) 
S. aureus Monitoring the effectiveness of antibiotics on 
biofilms on catheters planted in mice 
Kadurugamuwa et al. 
(2003a,b, 2004) ; Yu 
et al. (2005)  
S. aureus Monitoring staphylococcal foreign-body and 
deep-thigh-wound infections in mice 
Kuklin et al. (2003) 
S. aureus Investigating the effectiveness of antibiotics in a 
rat endocarditis model 
Xiong et al. (2005) 
S. aureus Monitoring implant-associated osteomyelitis 
infections  
Li et al. (2008) 
S. aureus Monitoring the spread of a staphylococcal 
infection on implanted biomaterial 
Engelsman et al. 
(2008) 
S. aureus Investigating the antimicrobial activity of 
daptomycin against S. aureus peritonitis 
infections  
Mortin et al. (2007) 
S. pneumoniae Investigating antibiotic treatments of infections 
in the lungs of mice 
Francis et al. (2001) 
S. pneumoniae Monitoring the spread of the pathogen 
throughout the central nervous system during 
acute stages of bacterial meningitis. 
Kadurugamuwa et al. 
(2005b,c) 
S. pneumoniae Monitoring the pathogenesis of pneumococcal 
meningitis simultaneous with the host response  
Kadurugamuwa et al. 
(2005a) 
S. pneumoniae Investigating whether virulence determinants 
play a role the transition of the pathogen 
between body sites  
Orihuela et al. (2004) 
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Pathogen Aim of study Reference 
L. monocytogenes Investigating the presence of the pathogen in the 
human gall bladder where replication occurs  
Hardy et al. (2004) 
L. monocytogenes Investigating the protective effect of bacteriocin-
producing L. salivarius UCC118 against the 
pathogenic infection 
Corr et al. (2007) 
 
Bioluminescent and fluorescent imaging studies have successfully been applied in other 
pharmaceutical fields. BLI can monitor tumor growth and metastasis noninvasively. Tumors 
are also detected earlier with BLI than traditional methods such as ultrasounds and clinical 
manifestation (Dickson et al., 2007; Jurczok et al., 2008).  The response in murine models to 
different cancer therapies can also be evaluated using BLI, i.e. an effective treatment will 
result in a decrease in tumor size which will be detected by a decrease in bioluminescence 
(Bartlett et al., 2007; Dickson et al., 2007; Jurczok et al., 2008).   
 
The expression of key genes involved the fields of neurology (Luo et al., 2006; Zhao et al., 
2006), cardiovascular (Davidson et al., 2005; Prasad et al., 2007), immunology (Tolar et al., 
2007), inflammation (Flanagan et al., 2007) and autoimmune diseases (Tarner et al., 2003) 
can be monitored using BLI. BLI also allows for the quantitative measurement of endogenous 
(Quesada et al., 2008) or transplanted (Folwer et al., 2005; Roth et al., 2006) pancreatic beta 
cells when studying diabetes.   
 
2.6. Animal models 
 
In vitro models investigate the activity and safety of antimicrobial peptides in static test 
systems while studies in humans can only assess morphological changes. For obvious reasons 
clinical trials in humans must abide to strict rules and regulations of ethical committees. 
Murine models are therefore the essential link between in vitro models and clinical trials for 
evaluating the safety and efficiency of antimicrobial peptides. Murine models provide a 
complete picture of the response the administration of antimicrobial peptides will have on the 
immune system, natural microflora and organs (histopathology) of mammals. Another 
advantage of murine models is that different variables can be manipulated that is not feasible 
in humans (Bakker-Woudenberg, 2003; Kips et al., 2003).  
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Scientists have used rats and mice as animal models since the eighteenth-century. The 
laboratory rat was the best functionally described mammalian model system. Rats were used 
in studies investigating cardiovascular diseases, metabolic disorders, neurological disorders, 
neurobiological disorders, organ transplantation, autoimmune diseases, cancer susceptibility 
and renal diseases. Rats have been used in studying diseases in the respiratory tract such as 
emphysema (Kuraki et al., 2002), influenza (Huang et al., 2004), pulmonary fibrosis (Spond 
et al., 2003) and pneumonia (Wan et al., 2006). Wistar rats were inbreeded from albino rats as 
early as 1909 by Helen Dean King at the Wistar Institute of Anatomy and Biology in 
Philadelphia (Krinke, 2000).  
 
The Human Genome Initiative selected the mouse as the first mammal to have its genome 
sequenced. Even though the physical appearances of humans and mice differ drastically, their 
genes are approximately 99% identical. The genes in humans and mice also function 
biologically in the same way. All this and the fact that genome of mice can be easily 
manipulated makes mice the ideal model organism for studying inherited human disorders 
(Hedrich, 2004). Mice are ideally situated for BLI studies because of their small size. As 
mentioned earlier with every centimeter of tissues depth, a 10-fold loss of photon intensity is 
observed (Sadikot and Blackwell, 2005). Mice have been used in studies investigating 
infections in the respiratory tract such as cystic fibrosis (Desigaux et al., 2005), lung cancer 
(Gagnadoux et al., 2005), influenza (Ogata and Shibata, 2008) and pneumonia (Scarff and 
Goldberg, 2008). 
 
Studying S. aureus infections in the respiratory tract of mice and rats each has their own 
unique drawbacks. Rats are less susceptible to S. aureus strains of human origin. Mice, on the 
other hand, are not the best model to use when studying unilateral pneumonia. Unilateral 
pneumonia has successfully been established in rats (Bakker-Woudenberg et al., 2002).  
 
S. aureus- related skin infection have been studied in mice (Abe et al., 1993; Stearne et al., 
2002) and rat models (Girard et al., 1993; Pattanayak and Sunita, 2008). Rats eliminate S. 
aureus at a faster rate from wound infections than mice and hamsters. Rats are also more 
resistant to localized wound infection (Donnelly and Stark, 1985). The skins of rats are found 
more resistant to staphylococcal exfoliative toxin, associated with staphylococcal scalded skin 
syndrome, than the skins of mice and humans (Machida, 1995).  
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Animal models have limitations even though they serve as a basis for clinical research in 
humans. The virulence and growth of infectious microorganism and the immunological 
response of the host differs from animals to humans. Furthermore, higher dosage of an 
antimicrobial agent is needed in rodents to acquire the same efficiency in humans. The reason 
for this is that rodents eliminate antibiotics at a faster rate. Animal models have also shown to 
produce slightly varied results as each model have their own set of advantages and 
disadvantages. Therefore, proper analysis and interpretation of data in animal models for 
clinical use is optimised when more than one animal model is used and their data compared 
(Bakker-Woudenberg, 2003).  
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Lantibiotics are small, ribosomally synthesized peptides with lanthionine rings and 
dehydrated amino acid residues. Nisin A was isolated from a strain of Lactococcus lactis subsp. 
lactis by Mattick and Hirsch (14), and the structure was published by Gross and Morell (10). 
Since then, a number of lantibiotics have been described, mostly from Lactococcus lactis, 
Streptococcus, Bacillus, Staphylococcus, and Streptomyces spp. (6).  
The nisin A operon has been studied in detail and consists of 11 genes, i.e. nisA, nisB, 
nisT, nisC, nisI, nisP, nisR, nisK, nisF, nisE, and nisG. The prepeptide is encoded by the 
structural gene nisA (2). NisB and nisC are involved in maturation of the lantibiotic, and nisT is 
involved in transport across the cell membrane (7). NisI encodes an immunity protein, and nisP 
encodes a putative serine protease involved in processing (8). NisR and nisK encode a putative 
regulatory protein and a putative histidine kinase, respectively (8, 20). NisF, nisE and nisG 
encode ATP-binding cassette transporters that are, together with nisI, responsible for immunity 
(18). The bacteriocin described in this paper is structurally different from nisins A, Z, Q, U and 
U2 and represents a sixth variation of the lantibiotic, designated nisin F.  
Lactic acid bacteria (LAB) were cultured in De Man Rogosa and Sharpe (MRS) broth 
(Biolab, Biolab Diagnostics, Midrand, South Africa) at 30°C, Staphylococcus aureus was 
cultured in brain heart infusion (BHI, Biolab) at 37°C, and Escherichia coli DH5 in Luria 
Bertani broth (Biolab) on a rotating wheel (model TC-7; New Brunswick Scientific Co., Inc., 
Edison, NJ) at 37°C. The target strains and growth conditions are listed in Table 1.  
Feces collected from the intestinal tract of Clarias gariepinus, a freshwater catfish from a 
river in Stellenbosch, South Africa, were inoculated into MRS broth and incubated for 24 h at 
30ºC. Cultures were streaked onto MRS agar (Biolab) plates and incubated for 24 h at 30ºC. 
Plates with fewer than 50 colonies were overlaid with BHI soft agar, each containing a pure 
culture of S. aureus. Colonies of lactic acid bacteria with the largest inhibition zones were 
selected and purified by streaking onto MRS agar. The presence of antimicrobial compounds in 
cell-free culture supernatants was confirmed by using the agarspot method (12).  
The strain that showed the best antimicrobial activity was selected and identified 
according to sugar fermentation reactions (API 50 CHL; bioMérieux, France), key differential 
characteristics (11) and 16S rRNA gene sequencing (9).  
Bacteriocin F was semipurified by ammonium sulphate precipitation and dialysis 
according to the method described by Sambrook et al. (16). The stability of the semipurified 
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bacteriocin against different enzymes, temperatures and pH levels was tested according to the 
method of Todorov and Dicks (19). The activity of samples was tested by using the agarspot 
method (12). The antimicrobial activity of the crude bacteriocin was tested against S. aureus and 
strains from the Laboratorium voor Microbiologie (LMG) panel (Table 1). Each strain (1 x 106 
CFU ml-1) was embedded in soft agar and the activity of nisin was tested as described before. The 
approximate molecular size of the BacF was determined by Tricine-sodium dodecyl sulfate 
(SDS)-polyacrylamide gel electrophoresis (17), as described by Van Reenen et al. (21). S. aureus 
K (106 CFU ml-1) was used as a sensitive strain.  
Strain F10 was cured from plasmids according to the method of de Kwaadsteniet et al. 
(4), modified by supplementing MRS broth with 20 to 80 µg ml-1 ethidium bromide (Sigma) 
instead of novobiocin or SDS.  
Genomic and plasmid DNA of strain F10 was isolated according to the method described 
by Dellaglio et al. (5) and by using a plasmid midi kit (Qiagen Inc., Valencia, CA), respectively. 
The size of the plasmid was determined from fragments generated by digesting with AccI 
(Boehringer Mannheim, GmbH, Germany), as described by Sambrook et al. (16).  
Genomic and plasmid DNA was amplified with primers designed from the structural gene 
of nisin Q (GenBank accession number AB100029). The following primers were used: nisin 
forward primer (nisF), 5-’ATGAGTACAAAAGATTTCAACTT-3’, and nisin reverse primer 
(nisR), 5’-TTATTTGCTTACGTGAACGC-3’. The amplification conditions were as follows: 1 
cycle of 94°C for 4 min; 35 cycles of 94°C for 1 min, 48°C for 30 s and 72°C for 7 s; and 1 cycle 
of 72°C for 7 min. PCR products were cleaned with QIAquick PCR purification kit (Qiagen) and 
sequenced with an ABI Prism TM377 DNA Sequencer (PE Biosystems SA). The exact molecular 
size of mature BacF (without leader peptide) was determined from the amino acid sequence 
deduced from the DNA sequence. DNA homology to sequences listed in GenBank was 
determined using the BLAST program (1).  
Sequencing of the 16S rRNA gene PCR product revealed 99% homology between strain 
F10, Lactococcus lactis subsp. lactis IL1403 and L. lactis strain KLDS 4.0319. Strain F10 is thus 
classified as L. lactis subsp. lactis. BacF inhibited the growth of two strains of S. aureus that have 
been isolated from patients diagnosed with sinusitis, Lactobacillus curvatus LMG 13553, 
Lactobacillus plantarum LMG 13556, Lactobacillus reuteri LMG 13557 and Staphylococcus 
carnosus LMG 13567 (Table 1). Antimicrobial activity was lost after treatment with pronase, 
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confirming that activity was conferred by a peptide. The bacteriocin remained active after 
treatment with amylase, pepsin and proteinase K. Levels of antimicrobial activity remained 
unchanged after 100 min at 90°C, but activity was lost after autoclaving. Activity was recorded 
over a broad pH range (from pH 2-10). According to SDS-polyacrylamide gel electrophoresis, 
the bacteriocin is between 6.5 and 14.3 kDa in size (Fig. 1). The size and the isoelectric point of 
the mature peptide (without the leader peptide) is respectively 3,457 kDa and 8.73, as deduced 
from the DNA sequence of the structural gene encoding the mature peptide.  
As far as we could determine, this is the second report of bacteriocin-producing strains of 
L. lactis isolated from fresh fish. The paper by Campos et al. (3) described strains of L. lactis 
with activity against Listeria monocytogenes and S. aureus, but did not characterize the 
bacteriocins.  
L. lactis F10 harbours a plasmid of approximately 24 kb. Strain F10 lost the ability to 
produce bacteriocin F after growth in the presence of ethidium bromide (30 µg ml-1), suggesting 
that the genes encoding the bacteriocin are located on the plasmid. The DNA primers that we 
have designed differ by one or two bases from the structural genes of nisin A, nisin Z and nisin U 
(not shown). The sequence of the DNA fragment amplified from strain F10 (GenBank accession 
number EU057979) is similar to the sequence recorded for the structural gene encoding nisin Z 
(GenBank accession number X61144) (15), except for valine instead of isoleucine at position 30. 
Homology was also recorded with nisin Q (GenBank accession number AB100029) (36), also 
having valine at position 30 (Fig. 2). However, bacF differs from nisin Q by having alanine at 
position 15 and not valine, and methionine at position 21 instead of leucine. It is interesting to 
note that nisin Q was also isolated from a river in Japan (22). Bacteriocin F is thus regarded as a 
new variety of nisin and is named nisin F.  
Nisin F proved very effective against clinical strains of S. aureus and may be used to 
prevent sinusitis. We are at present conducting research on Wistar rats to test this hypothesis. In 
previous studies, the lantibiotic mersacidin has been used to eradicate S. aureus from the 
respiratory tract of mice (13).  
This research was supported by a grant from the National Research Foundation (NRF), 
South Africa.  
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TABLE 1.  Target strains, growth conditions and spectrum of antimicrobial activity  
Target strain(s)a Growth medium and 
conditions 
Bacteriocin 
activity 
Lactobacillus acidophilus LMG 13550 MRS, 37°C anaerobic - 
Lactobacillus bulgaricus LMG 13551 MRS, 37°C anaerobic - 
Lactobacillus casei LMG 13552 MRS, 37°C anaerobic - 
Lactobacillus curvatus LMG 13553 MRS, 30°C anaerobic ++ 
Lactobacillus fermentum LMG 13554 MRS, 37°C anaerobic - 
Lactobacillus helveticus LMG 13555 MRS, 42°C anaerobic - 
Lactobacillus plantarum LMG 13556 MRS, 37°C anaerobic ++ 
Lactobacillus reuteri LMG 13557 MRS, 37°C anaerobic + 
Lactobacillus sake LMG 13558 MRS, 30°C anaerobic - 
Pediococcus pentosaceus LMG 13560, LMG 
13561 
MRS, 30°C anaerobic - 
Leuconostoc cremoris LMG 13562, LMG 13563 MRS, 30°C anaerobic - 
Streptococcus thermophilus LMG 13564, LMG 
13565 
MRS, 42°C anaerobic - 
Enterococcus faecalis LMG 13566 BHI, 37°C anaerobic - 
Staphylococcus carnosus LMG 13567 BHI, 37°C anaerobic +++ 
Listeria innocua LMG 13568 BHI, 30°C anaerobic - 
Bacillus cereus LMG 13569 BHI, 37°C anaerobic - 
Clostridium sporogenes LMG 13570 RCMb, 37°C anaerobic - 
Clostridium tyrobutyricum LMG 13571 RCM, 30°C anaerobic - 
Propionibacterium sp. LMG 13574 GYPc, 32°C anaerobic - 
Staphylococcus aureus K (own collection) BHI, 37°C aerobic +++ 
Staphylococcus aureus J (own collection) BHI, 37°C aerobic +++ 
a LMG, strains received from the Laboratorium voor Microbiologie, University of Ghent, Ghent, 
Belgium, now deposited into the Belgium Co-ordinated Collection of Micro-
organisms(BCCM)/LMG Culture Collection(http://bccm.belspo.be/about/lmg.php).  
bRCM, reinforced clostridium medium  
cGYP, glucose-yeast-peptone medium 
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FIG. 1. Separation of partially purified nisin F by SDS-PAGE. Lane 1: Rainbow low-range 
protein size marker RPN755 (Amersham International, UK). Lane 2: Protein band representing 
nisin F (arrow). Lane 3: Inhibition of S. aureus K (arrow), embedded in BHI soft agar (1%). 
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                   -10         1         10        20         30 
                                       
Nisin A MSTKDFNLDL VSVSKKDSGA SPRITSISLC TPGCKTGALM GCNMKTATCH CSIHVSK 
Nisin Z MSTKDFNLDL VSVSKKDSGA SPRITSISLC TPGCKTGALM GCNMKTATCN CSIHVSK 
Nisin Q MSTKDFNLDL VSVSKTDSGA STRITSISLC TPGCKTGVLM GCNLKTATCN CSVHVSK 
Nisin F MSTKDFNLDL VSVSKKDSGA SPRITSISLC TPGCKTGALM GCNMKTATCN CSVHVSK 
 
 
FIG. 2. Amino acid sequences of nisin F, deduced from the DNA sequence (GenBank accession 
number EU057979), and compared to the amino acid sequences of nisin A, nisin Z and nisin Q. 
The leader peptide of each nisin variant consists of 13 amino acids (from position -13 to -1), 
followed by amino acids encoding the mature protein (amino acid positions 1 to 34). Differences 
in amino acids are indicated with a black background. 
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Nisin F in the treatment of respiratory tract infections caused by 
Staphylococcus aureus 
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Aims: To determine the antimicrobial activity of nisin F against Staphylococcus aureus in the 
respiratory tract.  
Methods and Results:  The respiratory tract of non-immunosuppressed and 
immunosuppressed Wistar rats were colonised with 4 x 105 viable cells of S. aureus K and 
then treated by administering 8192 arbitrary units (AU) nisin F intranasal. Symptoms of 
pneumonia were detected in the trachea and lungs of immunosuppressed rats that had not 
been treated with nisin F. The trachea and lungs of immunosuppressed rats treated with nisin 
F were healthy. No significant differences were recorded in blood cell indices. The 
antimicrobial activity of low concentrations nisin F (80 - 320 AU ml-1) was slightly stimulated 
by lysozyme and lactoferrin. 
Conclusions: Nisin F inhibited the growth of S. aureus K in the respiratory tract of 
immunocompromised rats. Treatment with nisin F at 8192 AU proofed safe, as the trachea, 
lungs, bronchi and haematology of the rats appeared normal. 
Significance and Impact of the Study: Nisin F is nontoxic and may be used to control 
respiratory tract infections caused by S. aureus. This is, however, a preliminary study with an 
animal model and need to be confirmed with studies on humans. 
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Introduction 
 
Staphylococcus aureus is an important pathogen in upper (Brook 2005; Grzegorowski and 
Szydlowski 2005; Verhoeff et al. 2006) and lower respiratory tract infections (Harmanci et al. 
2002; Saiman 2004; Weber et al. 2007). Development of new antistaphylococcal agents is 
driven by the emergence of resistance to methicillin, macrolides, lincosamides, 
flouroquinlones, tetracyclines, aminoglycosides, chloramphenicol (Almer et al. 2002), 
vancomycin (Centers for Disease Control and Prevention 2004), mupirocin (Watanabe et al. 
2001) and the more recently developed antimicrobials quinupristin-dalfopristin (Fagon et al. 
2000), linezolid (Peeters and Sarria 2005) and daptomycin (Skiest 2006). 
Lysozyme and lactoferrin are the two most abundantly secreted antimicrobial proteins 
in airway secretions of humans (Brogan et al. 1975; Harbitz et al. 1984; Wilson 2005). These 
proteins are antimicrobial against S. aureus and have a synergistic effect with nisin (Nattress 
et al. 2001; Murdock et al. 2007). The protective effect of lactic acid bacteria against 
respiratory tract infections has been studied in animal models (Alvarez et al. 2001; Racedo et 
al. 2006) and humans (Glück and Gebbers 2003; Cobo Sanz et al. 2006). Studies on the 
protective effect of bacteriocins produced by lactic acid bacteria against respiratory tract 
infections are limited.  Kruszewska et al. (2004) repressed the growth of methicillin-resistant 
S. aureus (MRSA) strains in the respiratory tract of mice with mersacidin, a lantibiotic 
produced by Bacillus sp. HIL Y-85 54728. Similar studies with nisin, a lantibiotic produced 
by Lactococcus lactis subsp. lactis, did not eradicate S. aureus from the nasal tract of rats 
(Kokai-Kun et al. 2003).  
In a previous paper (De Kwaadsteniet et al. 2008), we described nisin F produced by 
L. lactis subsp. lactis F10 and reported on the in vitro activity against clinical strains of S. 
aureus.  In the present study, non-immunosuppressed and immunosuppressed rats were 
intranasally infected with a clinical strain of S. aureus and then treated with nisin F.  Blood 
cell counts and the histology of lung and trachea tissue from rats in both groups were 
compared. The safety of nisin F was determined by administering the peptide to non-
immunosuppressed and immunosuppressed rats intranasally. 
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Materials and methods 
 
Bacterial strains and culture conditions  
 
Lactococcus lactis subsp. lactis F10 was cultured in De Man Rogosa and Sharpe (MRS) broth 
(Biolab, Biolab Diagnostics, Midrand, South Africa) at 30°C and Staphylococcus aureus K in 
brain heart infusion (BHI, Biolab) at 37°C.  Biard-Parker agar base (Biolab) was used as 
selective medium for S. aureus K, isolated from the nasal cavity of a patient with acute 
sinusitis. 
 
Nisin F preparation  
 
Nisin F, produced by L. lactis subsp. lactis F10 (De Kwaadsteniet et al. 2008), was semi-
purified by ammonium sulphate precipitation and dialysed according to the method described 
by Sambrook et al. (1989). The peptide was concentrated by freeze-drying and resuspended in 
sterile physiological saline.  Antimicrobial activity was determined by using the agar-spot test 
method and expressed as arbitrary units (AU) per millilitre.  One AU is the reciprocal of the 
highest serial two-fold dilution showing a clear zone of inhibition of the indicator strain (Van 
Reenen et al. 1998). The indicator strain was an 18-h-old culture of S. aureus K  (106 CFU 
ml-1), embedded in BHI soft agar (1%). 
 
Synergistic effect of nisin F with lysozyme and lactoferrin 
 
The antimicrobial activity of nisin F, lysozyme, lactoferrin and combinations thereof were 
tested as follows: Nisin F was added to 100 l BHI to yield final concentrations of 1280, 320, 
and 160AU ml-1, respectively (Table 1). In another set, lysozyme (Roche Diagnostic Gmbh, 
Manheim, Germany) and lactoferrin (Sigma Diagnostics, St. Louis, USA) were added to 100 
l BHI to yield a final concentration of 500 g ml-1 (Table 1). Combinations of nisin F, 
lysozyme and lactoferrin were also prepared (Table 1). The suspensions were inoculated into 
separate wells of a sterile microtitre plate and then inoculated with S. aureus K to yield 105 
viable cells. Nisin F, lysozyme and lactoferrin at the same concentrations, but not inoculated 
with S. aureus K served as controls. The microtitre plate was incubated at 37ºC for 24 h and 
OD-readings taken at 595 nm (Model 680 Microplate Reader, Hercules, CA, USA, Bio-Rad). 
All experiments were carried out in triplicate. 
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Animal model and inoculation procedure  
 
Approval for the experiments was obtained from the Animal Ethics Committee of 
Stellenbosch University (ethics reference number 2005B02003).  Wistar male rats were 
divided into eight groups and housed in plastic cages in animal rooms with constant 
environmental conditions. Each group contained six rats. All rats received a standard rodent 
diet.  The immunity of rats in groups 3 and 4 was suppressed by adding dexamethasone (2.5 
mg l-1) to their drinking water for the first six days. An inoculum of S. aureus K was prepared 
by growing the cells in BHI for 18 h at 37°C.  The cells were harvested (10 000 g, 10 min, 
4°C), washed three times with 10 ml sterile physiological saline, resuspended in 10 ml sterile 
skim milk (10% w/v) and 4 ml dispensed into freeze-drying ampules. After 24 h of freeze-
drying, the cells were resuspended in sterile saline to 107 CFU ml-1. On days 5, 6, 7, and 8 the 
rats in the groups 1 to 4 were intranasally infected with 4 x 105 viable cells of S. aureus K (2 x 
10 l of 107 CFU ml-1 per nostril) per day.   On days 9, 10, 11 and 12 rats in groups 1 and 3 
were treated with 8192 AU nisin F (2 x 10 µl per nostril) and rats in groups 2 and 4 with 
sterile physiological saline (2 x 10 µl per nostril).   
The safety of nisin F was tested by conducting a similar experiment. Rats in groups 7 
and 8 received dexamethasone for the first six days as described before. On days 9, 10, 11 and 
12 rats in groups 5 and 7 received 8912 AU nisin F and groups 6 and 8 sterile physiological 
saline, as described before. None of the rats in groups 5 to 8 were infected with S. aureus K.  
On day 13 all the rats were euthanized by an overdose with pentobarbitone sodium 
(Centaur Labs, Bayer Animal Health Isando, South Africa) administered intraperitoneally.   
 
Testing for adverse effects  
 
The rats were weighed and their feed and water intake determined on a daily basis.  Blood 
from rats infected with S. aureus K was plated onto Baird-Parker agar (Biolab) and the plates 
incubated at 37°C for 24 h. 
 
Histological studies 
 
The trachea, bronchi and lungs of three rats from each group were aseptically removed, fixed 
in 4% (v/v) formaldehyde (PBS) for 24 h at 25ºC, embedded in paraffin, sectioned and stained 
with hematoxylin and eosin (H&E). The samples were processed and analysed at Pathcare 
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Veterinary Pathologists (Pathcare, Dietrich, Voigt, Mia and Partners, Goodwood, South 
Africa). 
 
Haematology 
 
Blood samples were collected from the rats directly after they were euthanized.  Total blood 
counts were determined on fresh blood with an automated haematology counter (Beckman 
Coulter Hematology Analyzer LH; Beckman Coulter, Inc., CA, USA). All tests were 
conducted by Pathcare Veterinary Pathologists. 
 
Results 
 
Nisin preparation and dosage  
 
The antimicrobial activity of concentrated semi-purified nisin F was 204 800 AU ml-1, as 
determined by using S. aureus K as target strain.  The daily dosage with nisin F was thus 8192 
AU (2 x 10 µl per nostril) per rat for both the infection and nisin F toxicity studies. 
 
Effect of nisin F, alone and in combination with lysozyme and lactoferrin, on the growth 
of S. aureus K 
 
Changes recorded in OD-readings of S. aureus K after incubation in the presence of nisin F, 
nisin F supplemented with lysozyme and lactoferrin, and lysozyme and lactoferrin without 
nisin F, are listed in Table 1. In the absence of nisin F, the growth of S. aureus K increased to 
OD (595 nm) = 2.0. Nisin at 1280 AU ml-1 prevented the growth of S. aureus K (OD595nm = 
0.1). However, low concentrations of nisin F (160 to 320 AU ml-1) stimulated the growth of S. 
aureus K slightly (OD595nm = 0.9 to 1.1). No significant differences in the growth of S. aureus 
K were recorded when the cells were treated with nisin F (1280 AU ml-1) and the same level 
of nisin F in combination with either lysozyme or lactoferrin (OD595nm = 0.1 to 0.2).  Nisin F 
at 320 AU ml-1 combined with lysozyme completely inhibited the growth of S. aureus K 
(OD595nm = 0). Synergism was observed between nisin F (at 320 and 160 AU ml-1) in 
combination with either lysozyme and lactoferrin. 
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Testing for adverse effects  
 
No significant differences were recorded in weight gain, and water and feed intake for rats in 
groups 1 – 4 (not shown).  Bacterial growth was recorded in blood sampled from one of the 
rats in group 4 (immunosuppressed, not treated with nisin F and infected with S. aureus K). 
Small (1-5 mm) black colonies, surrounded by clear zones, characteristic of S. aureus, were 
visible on the Baird-Parker agar plates. The lungs of the same infected animal had clearly 
visible necrotic lesions (not shown). No bacteremia or necrotic lesions were observed on 
lungs of rats in groups 1, 2 and 3. No significant differences were recorded in weight gain, 
and water and feed intake for rats in the nisin toxicity trial (groups 5 - 8). 
 
Histology  
 
No significant histopathology were recorded in lung tissue collected from rats in group 1 
(non-immunosuppressed, infected with S. aureus K and treated with nisin F), group 2 (non 
immunosuppressed, infected with S. aureus K and treated with sterile physiological saline), 
and group 3 (immunosuppressed, infected with S. aureus K, and treated with nisin F) (Fig. 
1a). Severe symptoms of pneumonia were detected in lung tissue sampled from rats in group 
4 (immunosuppressed, infected with S. aureus K, and treated with sterile physiological 
saline). The alveoli of the lungs from rats in group 4 were clearly obliterated due to the 
infiltration of macrophages, granulocytes and lymphocytes, and the proliferation of fibroblasts 
and alveolar epithelial cells (Fig. 1b). The trachea of the same rats showed signs of mucosal 
hyperplasia, with infiltration of lymphocytes and a few mast cells (Fig. 1d). No mucosal 
hyperplasia was observed in the trachea of rats from group 3 (immunosuppressed, infected 
with S. aureus K, and treated with nisin F) (Fig. 1c). No histological changes or differences 
were detected in the bronchi of rats in groups 1 to 4.  
The histology of the trachea, lungs and bronchi of non-immunosuppressed and 
immunosuppressed rats that have been treated with nisin F (groups 5 and 7) and sterile 
physiological saline (groups 6 and 8), and not infected with S. aureus K, appeared healthy 
(not shown). 
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Haematology  
 
The number of white blood cells, lymphocytes and neutrophils recorded in blood samples 
collected from non-immunosuppressed and immunosuppressed rats that have been infected 
with S. aureus K (groups 1 - 4) did not differ significantly (Fig. 2). The number of white 
blood cells, lymphocytes and neutrophils of the rats in the nisin F toxicity trial (Fig. 2) also 
did not differ between the nisin-treated rats (groups 5 and 7) and saline-treated rats (groups 6 
and 8). No significant differences were detected in the red blood cell indices (Table 2) 
between the experimental and control groups for both the infection trial, i.e. groups 1 and 2 
for non-immunosuppressed rats and groups 3 and 4 for immunosuppressed rats, and for the 
nisin F toxicity trial, i.e. groups 5 and 6 for non-immunosuppressed rats and groups 7 and 8 
for immunosuppressed rats (Table 2). The red blood cell distribution width (RDW) of rats that 
have not been infected with S. aureus K (groups 5 - 8) was slightly higher compared to rats 
that have been infected (groups 1 - 4). 
 
Discussion 
 
Growth of S. aureus K was clearly inhibited by high levels of nisin (1280 AU ml-1), whether 
tested alone, or in combination with lysozyme and lactoferrin. Less growth inhibition of S. 
aureus K at lower concentrations of nisin F (160 - 320 AU ml-1) was to be expected. It is also 
not surprising to have recorded a slight increase in antimicrobial activity when nisin F was 
tested in combination with lysozyme and lactoferrin. This is indicative of synergistic 
antimicrobial activity, perhaps easier to observe in the presence of lower levels of nisin (160 - 
320 AU ml-1) than an overwhelming concentration (1280 AU ml-1). Complete growth 
inhibition of S. aureus K was observed when 320 AU ml-1 nisin F was tested in combination 
with lysozyme. 
Lysozyme and lactoferrin are present at relatively high concentrations in the upper 
respiratory tract of humans and in sputum at approximately 500 g ml-1 (Brogan et al. 1975; 
Harbitz et al. 1984; Wilson 2005). Previous studies have shown a synergistic effect between 
nisin and lysozyme (Nattress et al. 2001) and nisin and lactoferrin (Murdock et al. 2007). 
Nisin prevents cell growth by binding to the cell wall precursor lipid II and destabilising the 
cell membrane, whereas lysozyme damages the glycosidic bond between N-
acetylglucosamine and N-acetylmuramic acid residues in the peptidoglycan (Ganz 2004). 
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Lactoferrin inhibits microbial growth by sequestering iron involved in respiration (Arnold et 
al. 1977).  
Non-immunosuppressed rats dosed with S. aureus K did not develop symptoms of 
respiratory tract infections, confirming previous reports that the immune system of rats has to 
be compromised when studying S. aureus respiratory tract infections (Kruszewska et al. 
2004). S. aureus have been associated with pneumonia, especially nosocomial pneumonia 
(Weber et al. 2007) and community-acquired pneumonia (Micek et al. 2007). It is thus not 
surprising that immunosuppressed rats infected with S. aureus K and not treated with nisin F 
developed severe symptoms of pneumonia, i.e. obliterated alveoli in lungs and mucosal 
hyperplasia in trachea. Mucosal hyperplasia may be due to increased production of mucus in 
the infected area (Fig. 1d). This is expected, as the up-regulation of mucin genes from by 
products produced by S. aureus has been reported (Dohrman et al. 1998; Basbaum et al. 
1999).  
Necrotic lesions observed in the lung tissue and bacteremia detected in 
immunosuppressed rats infected with S. aureus K is indicative of damaged lung tissue 
through which the pathogen migrates into the blood stream. Immunosuppressed and infected 
rats treated with nisin F had no symptoms of pneumonia, mucosal hyperplasia, blood 
contamination or necrotic lesions, suggesting that the lantibiotic suppressed the growth of S. 
aureus K in vivo. Kokai-Kun et al. (2003), on the other hand, reported no inhibition of S. 
aureus in the nasal tract of cotton rats and concluded that nisin is either inactivated or 
absorbed in the nares. Another possible explanation is the formation of biofilms in the nasal 
tract, which could render the strains more resistant to nisin (Bendouah et al. 2006).  
No histology changes were observed in the lungs, trachea and bronchi of rats in the 
nisin F toxicity trial (non-immunosuppressed and immunosuppressed groups). No differences 
in weight gain and food and water consumption were recorded. Nisin F had no effect on the 
white cell, lymphocyte and neutrophil production in the rat model. The red blood cell indices 
of rats treated with nisin F was similar to that recorded for rats treated with saline. Based on 
these results, nisin F is nontoxic and safe to use in the treatment of upper-respiratory 
infections.  
As far as we could determine, this is the first successful report on a nisin variant being 
used to control intranasal S. aureus infections. Although murine models serve as an essential 
link between in vitro models and human clinical trails, the data presented in this study is 
preliminary and will have to be confirmed with studies on human volunteers before nisin F 
may be declared safe for human application. 
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Table 1 Optical density readings (at 595 nm) of S. aureus K after incubation with nisin F, 
lysozyme, lactoferrin, and a combination of nisin F and lysozyme or lactoferrin, respectively  
 In the absence of 
lysozyme and 
lactoferrin 
Lysozyme 500 g ml-1 Lactoferrin 500 g ml-1 
Nisin F 1280 AUa ml-1 0.08±0.06 0.14±0.02 0.15±0.04 
Nisin F 320 AU ml-1 1.11±0.23 0 0.43±0.11 
Nisin F 160 AU ml-1 0.89±0.06 0.44±0.01 0.47±0.02 
  1.66±0.04 0.88±0.03 
Standard deviation displayed is a mean value of three repeats per experiment (n = 3).  
AU, antimicrobial units. 
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Figure 1 Histological images of respiratory tract tissue from immunosuppressed rats infected 
with S. aureus K and then treated with either nisin F or sterile physiological saline. (a, c) 
Lungs and trachea, respectively, of rats from group 3 (immunosuppressed, infected and 
treated with nisin F). (b, d) Lungs and trachea, respectively, of rats from group 4 
(immunosuppressed, infected and treated with saline). Differences observed in alveoli and 
trachea (no mucosal hyperplasia compared to mucosal hyperplasia) is shown by arrows. 
Magnification: 400x 
 
 
 
 
 
 
 
 
 
 
 
(a) (b) 
(d) (c) 
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Figure 2 Cell counts of total white blood cells (striped column), neutrophils (white column), 
and lymphocytes (grey column). Group 1: infected, non-immunosuppressed nisin F-treated 
rats, group 2: infected, non-immunosuppressed saline treated, group 3: infected, 
immunosuppressed nisin F-treated rats, group 4: infected, immunosuppressed saline treated 
rats, group 5: noninfected non-immunosuppressed nisin F-treated rats, group 6: noninfected 
non-immunosuppressed saline treated group, group 7: noninfected immunosuppressed nisin 
F-treated rats and group 8: noninfected immunosuppressed saline treated rats.  
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Table 2 The red blood cell indices 
Red blood cell indices  Groupe 1 Group 2 Group 3 Group 4 Group 5 Group 6 Group 7 Group 8 
Haemoglobin (g dL-1) 14.85±0.78 14.92±0.92 15.17±0.72 15.73±0.54 14.1±0.16 13.70±0.37 13.08±0.61 12.45±1.21 
Haematocrit (L-1) 0.42±0.04 0.43±0.03 0.44±0.02 0.46±0.01 0.41±0.01 0.38±0.02 0.38±0.02 0.37±0.03 
MCVa (femtoliters) 59.7±0.5 58.5±1.1 58.8±1.2 57.2±1.8 58.5±1.9 59.83±2.0 63.83±1.9 63±3.4 
MCHb (pg) 21.0±0.9 20.5±0.6 20.3±0.5 19.5±0.6 20.25±0.5 21.17±1.2 21.67±0.8 21.33±0.8 
MCHCc (g dL-1) 35.3±1.2 35.3±0.8 34.3±0.5 34.3±0.5 34.75±0.5 35.67±0.8 34.33±0.5 33.83±1.2 
RDWd (%) 11.4±0.5 11.1±0.2 12.4±0.5 11.6±0.3 14.48±0.8 15.27±0.9 17.27±1.2 18.12±3.7 
aMCV, mean corpuscular volume 
bMCH, mean corpuscular haemoglobin  
cMCHC, mean corpuscular haemoglobin concentration 
dRDW, red blood cell distribution width 
eGroup 1: infected, non-immunosuppressed nisin F-treated rats, group 2: infected, non-immunosuppressed saline treated, group 3: infected, 
immunosuppressed nisin F-treated rats, group 4: infected, immunosuppressed saline treated rats, group 5: noninfected non-immunosuppressed nisin F-
treated rats, group 6: noninfected non-immunosuppressed saline treated group, group 7: noninfected immunosuppressed nisin F-treated rats and group 
8: noninfected immunosuppressed saline treated rats 
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Nisin F in the treatment of subcutaneous skin infections by 
monitoring bioluminescent Staphylococcus aureus noninvasively 
and in real-time 
 
M. de Kwaadsteniet, C. A. van Reenen and L.M.T. Dicks* 
Department of Microbiology, University of Stellenbosch, 7600 Stellenbosch, South Africa 
 
The potential of nisin F as an antimicrobial agent in treating subcutaneous skin infections was 
tested in vivo by infecting C57BL/6 mice with a bioluminescent Staphylococcus aureus 
strains (Xen 36). Strain Xen 36 has the luxABCDE operon located on a native plasmid. Mice 
were grouped into four groups. Infected with strain Xen 36 and treated with nisin F, infected 
with strain Xen 36 and treated with saline (placebo), not infected and treated with nisin 
(control) and not infected and not treated (control). The immune systems of the mice were 
suppressed with deksamethasone. Mice were treated with either nisin F or sterile 
physiological saline 24 h and 48 h after infection with subcutaneously injected S. aureus Xen 
36 (4 x 106 cfu). Histology and bioluminescent flux measurements revealed no significant 
difference between infected mice treated with nisin and saline, respectively. However, 
infected mice treated with nisin F had an increased number of polymorphonuclear cells when 
compared with infected mice treated with saline. Also, not infected mice treated with nisin F 
had an influx of polymorphonuclear cells. Nisin F is ineffective in combating deep dermal 
staphylococcal infections. The apparent immune modulation that subcutaneously infected 
nisin had needs to be further investigated.    
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Introduction 
 
Skin and soft tissue infections (SSTIs) are an immense health problem with infections ranging 
from mild folliculitis, furunculosis and atopic dermatitis to severe cases of necrotizing 
fasciitis.1-3 Prolonged and ineffectively treated SSTIs may lead to endocartitis, osteomyelitis, 
meningitis, brain abscesses and pneumonia.4,5 Mild SSTIs are treated with oral antimicrobial 
agents but complicated SSTIs lead to hospitalization, surgical intervention and treatment with 
intravenous antibiotics.6,7  
The SENTRY antibiotic surveillance program reported that Staphylococcus aureus 
was the most frequently isolated pathogen isolated from SSTIs in North America, Latin 
America and Europe.8 SSTIs reported in the emergency departments in the US increased from 
1.2 million visits in 1993 to 3.4 million visits in 2005. This increase co-incided with the 
emergence of community-associated methicillin resistant S. aureus. Although no direct 
correlation can be made, this theory is supported by the fact that physicians started treating 
SSTIs from 2001 with antibiotics active against community-associated MRSA, namely 
trimethoprim-sulfamethoxazole and clindamycin.9 The occurrence of antibiotic resistance 
among strains of S. aureus causing SSTIs has been reported by numerous researchers 
worldwide10-12 and emphasizes the need for the development of alternative and more effective 
antimicrobial agents. 
Optical imaging and bioluminescent reporter systems have in recent years advanced to 
a point where researchers can monitor bacterial infections in the same animal noninvasively 
and in real-time over multiple time-points.13-17  Numerous studies have shown a strong 
correlation between the bioluminescence flux measurements generated from these genetically 
engineered bacteria and viable cell numbers in tissue homogenates.14-17,18-20 Bioluminescent 
imaging (BLI) has been used for studying skin infections and the treatment of these infections 
with antibiotics and photodynamic therapy.18,21,22   
Nisin F is a natural nisin variant with in vitro antimicrobial activity towards clinical 
strains of S. aureus.23 Previously, we demonstrated that nisin F may play a protective role 
against S. aureus infections in the respiratory tract of Wistar rats.24 The aim of this study is to 
investigate the antimicrobial effect of nisin F against S. aureus Xen 36, injected 
subcutaneously, in C57BL/6 mice using BLI. 
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Materials and Methods 
 
Bacterial strains and culture conditions 
 
Staphylococcus aureus Xen 36 (Caliper Life Sciences, Hopkinton, MA) has a stable copy of 
the modified Photorhabdus luminescence luxABCDE operon at a single integration site on a 
native plasmid.15 The parental strain was S. aureus ATCC 49525, a clinical strain isolated 
from a bacteremia patient. S. aureus Xen 36 was cultured in brain heart infusion (BHI) 
(Biolab, Biolab Diagnostics, Midrand, South Africa) at 37°C. Lactococcus lactis subsp. lactis 
F10 was cultured in De Man Rogosa Sharpe (MRS) broth (Biolab) at 30°C. 
 
In vitro studies 
 
Nisin F, produced by L. lactis subsp. lactis F10,23 was semipurified by ammonium sulphate 
precipitation and dialysis according to the method described by Sambrook et al.25 The peptide 
was concentrated by freeze-drying in ampules.  Antimicrobial activity was determined by 
using the agar-spot test method and expressed as arbitrary units (AU) per millilitre.  One AU 
is the reciprocal of the highest serial two-fold dilution showing a clear zone of inhibition of 
the indicator strain.26 The indicator strain was an 18 h-old culture of S. aureus Xen 36 (106 
cfu/ml1), embedded in BHI soft agar (1%). 
  
Animal model  
 
Approval for the experiments was obtained from the Animal Ethics Committee of 
Stellenbosch University (ethics reference number 200801024). C57BL/6 mice weighing 
between 20 and 25 g were divided into four groups (six per group). The hair on the back of 
each mouse was removed with Veet Lotion Hair Remover (Reckitt Benckiser, Elandsfontein, 
South Africa). The mice in group 1 were infected with S. aureus Xen 36 and treated with nisin 
F. Group 2 mice were infected with S. aureus Xen 36 and treated with sterile physiological 
saline. Group 3 mice were treated with nisin F, but not infected with S. aureus Xen 36. Group 
4 mice were not infected and not treated. The mice were housed in plastic cages in animal 
rooms with constant environmental conditions and fed a standard rodent diet.  The immune 
systems of the mice in all four groups were suppressed by adding deksamethasone to their 
drinking water (2.5 mg/L). Mice in group 1 and 2 were infected on day 1 by injecting 10 l of 
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S. aureus Xen 36 (4 x 106 cfu) beneath the skin of each animal. Treatment took place on day 2 
and 3 and consisted of 10 l nisin F (256 AU) for groups 1 and 3 and 10 l sterile 
physiological saline for group 2, injected subcutaneously.   
On day 6 all the mice were euthanased by an overdose with pentobarbitone sodium 
(Centaur Labs, Bayer Animal Health Isando, South Africa) administered intraperitoneally.  
The chest cavity was opened and blood samples collected by cardiac puncture of the right 
ventricle.  
 
In vivo imaging 
 
Mice, while under 2% isoflurane gas anesthesia, were imaged each day for a maximum of 5 
min using a CCD camera (IVIS® 100 Imaging System, Caliper Life Sciences). Living Image 
software (Caliper Life Sciences) was used to detect and quantify total photon emission 
(number of photons/s/cm2) from defined regions of interest (ROI) within each image.  
 
Histological studies 
 
Sections of the skins of three rats from each group were aseptically removed, fixed in 4% 
(v/v) formaldehyde (PBS) for 24 h at 25ºC, embedded in paraffin, sectioned and stained with 
hematoxylin and eosin (H&E). The samples were processed and analysed at Pathcare 
Veterinary Pathologists (Pathcare, Dietrich, Voigt, Mia and Partners, Goodwood, South 
Africa). 
 
Results and discussion 
 
Research on the potential of nisin in treating skin and subcutaneous skin infections is 
very limited. Valenta et al. concluded that nisin is stable and antimicrobial against S. aureus 
in different topical formulations in in vitro studies.27 The only study that investigated the in 
vivo effect of nisin, or any other bacteriocin, administered subcutaneously was performed by 
Ghiselli et al. Grafts were implanted subcutaneously and infected with Staphylococcus 
epidermis. Grafts soaked in nisin before implantation had lower infection counts (6.2 x 
103±1.3 x 103 cfu) than the grafts not treated (4.8 x 107±2.0 x 106 cfu).28  
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BLI was used in this study to determine whether nisin F injected subcutaneously 
protected mice against deep dermal staphylococcal infection. Histology was performed to 
detect any pathology and verify data collected from BLI.  
The total photon emissions from infected mice treated with nisin F (group 1) and 
saline (group 2), respectively, increased by 0.5 log 24 h after infection with S. aureus Xen 36 
(Figures 1 and 2). Abscesses underneath the skin were also visible after 24 h in mice from 
both groups. At 24 h and 48 h either nisin F (group 1) or sterile physiological saline (group 2) 
was administered subcutaneously. No significant difference could be detected between group 
1 and group 2 throughout the duration of the trail (Figures 1 and 2). Nisin F had therefore no 
antimicrobial activity against S. aureus Xen 36 in vivo. Bunce et al. reported that the degree 
of cutaneous infections caused by S. aureus varies from mouse to mouse. The onset of lesions 
also differed between the mice. Both these observations are also seen among human 
cutaneous staphylococcal infections.29 This can be a possible explanation for the high 
standard deviation in the bioluminescent flux measurements in the infected groups.   
Subacute active necrotic dermatitis and cellulitis were detected in the mice from group 
1 (infected and treated with nisin F). Multifocal areas of necrosis with complete loss of 
cellular detail were detected in the dermal stromas and deeper subcuticular tissues. These 
areas were associated with a high infiltration of polymorphonuclear cells, as well as 
lymphocytes and fibroblasts in the surrounding tissues. Occasional hair fragments were also 
visible (Figure 3a). Subacute to active dermatitis were detected in the mice from group 2 
(infected and treated with saline). Multifocal areas of necrosis with complete loss of cellular 
detail were also detected in the dermal stromas of the mice in group 2. Small hair fragments 
were also visible. However, a reduction in the number of polymorphonuclear cells in the 
lesions of mice treated with saline was observed (Figure 3b). The innate immune system of 
mice treated with nisin may have been more actively combating the infection since they had a 
higher polymorphonuclear cell density. The other possible explanation is that the 
administration of nisin could have modulated the innate immune system. 
 The total photon emissions from mice not infected and treated with nisin F (group 3) 
and mice not infected and not treated (group 4) were significantly lower than the total photon 
emissons from the infected groups (group 1 and 2), as expected. The total photon emissions 
from group 3 were slightly higher than the total photon emissions from group 4 (Figures 1 and 
2). This is an interesting phenomenon since the only variable between the two groups was the 
administration of nisin which does not bioluminesce. 
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 The histopathology of the skin of the mice in group 3 (not infected and treated with 
nisin F) ranged from no histological changes to focal acute dermatitis. Focal areas of oedema 
with mild infiltration of polymorphonulear cells as well as a few macrophages were detected 
in the dermal stroma of the mouse with focal acute dermatitis and the mouse with mild focal 
dermal oedema. The cytoplasma of the macrophages were discoloured in the latter mouse, 
probably due to pigment in the protein product (Figure 3c). Nisin F may thus modulate the 
innate immune system when injected subcutaneously. No histological changes were observed 
in the mice from group 4 (not infected and not treated) (Figure 3d).  
Future research is needed to evaluate nisin F as a topical antimicrobial in superficial 
skin infections. Kugelberg et al. have established S. aureus-related superficial skin infection 
models by removing the epidermis of mice skin with tape stripping.30 The application of nisin 
F as a topical agent will not only determine if it is more effective as an antimicrobial agent, 
but will also investigate whether the innate immune system will be aggravated. The effect that 
nisin and other lantibiotics have on the immune system in murine models is an important 
topic since research on the medical applications of lantibiotics is increasing. This is especially 
relevant when applying nisin as an antimicrobial agent for skin infections since atopic 
dermatitis, although not yet defined as an auto-immune disease, is initiated and maintained by 
the actions of inflammatory cells such as cytokines, chemokines and T-cells.31  
 In conclusion we have reported that the subcutaneous administration of nisin F had no 
effect on deep dermal staphylococcal infections. Furthermore, the administration of nisin F 
subcutaneously may have modulated the innate immune system.   
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Figure 1. A representative mouse from each group depicts a time series of photon detection 
(photons per second per square centimeter) from metabolically active S. aureus Xen 36. 
Group1: infected and treated with nisin F, group 2: infected and treated with saline, group 3: 
not infected and treated with nisin F and group 4: not infected and not treated.  
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Figure 2. Photon emissions (photons/s/cm2/sr) from defined ROI within selected images of 
the mice in each group. Group1 (-•-): infected and treated with nisin F, group 2 (--): infected 
and treated with saline, group 3 (--): not infected and treated with nisin F and group 4 (--): 
not infected and not treated.  
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Figure 3. Histology images of skin tissue from (a) an infected and treated with nisin F mouse, 
(b) an infected and treated with saline mouse, (c) a not infected and treated with nisin F 
mouse and (d) a not infected and not treated mouse.  
 
 
 
 
(a) (b) 
(c) (d) 
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Chapter 6 
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General discussion and conclusions 
 
Traditionally, bacteriocins have been used in food preservation. Recently, the potential 
application of bacteriocins as an alternative to antibiotics has been explored. This study 
entailed the isolation and characterization of a lantibiotic, nisin F, proven to be active against 
clinical Staphylococcus aureus strains in vitro and the potential antimicrobial activity in vivo 
in murine models. 
 
Lactococcus lactis subsp. lactis F10, isolated from fresh water catfish, Clarias gariepinus, 
produces a lantibiotic, nisin F, active against two clinical Staphylococcus aureus strains, 
Staphylococcus carnosus LMG 13556, Lactobacillus curvatus LMG 13553, Lactobacillus 
plantarum LMG 13556 and Lactobacillus reuteri LMG 13557.  Plasmid curing with 30 µg 
ml-1 ethidium bromide revealed that the genes encoding the production, immunity and 
secretion of the peptide are located on a 24-kb plasmid.  Sequencing of the structural gene 
revealed that nisin F relates to nisin Z by having asparagine at position 27 and not histidine as 
recorded for nisin A.  However, nisin F differs from nisin Z by having valine at position 30 
instead of isoleucine and is in this respect similar to nisin Q.  Nisin F differs from nisin Q by 
having alanine at position 15 and not valine, and methionine at position 21 instead of leucine. 
Nisin Q was also isolated from a water source, namely a river in Japan (Zendo et al., 2003).  
 
Nisin is active against Gram-positive pathogenic bacteria of fish (Elotmani and Assobhei, 
2004) and modulates the immune system of turbot (Villamil et al., 2003). Both of these 
mechanisms can protect fish against disease and may explain the presence of nisin-producing 
L. lactis subsp. lactis strains in freshwater catfish and in rivers of Japan (de Kwaadsteniet et 
al., 2008; Zendo et al., 2003). The interest in using live lactic acid bacteria as probiotics in 
fish farming further supports this theory (Gatesoupe, 2008). Nisin F is regarded as a new 
variant of the nisin family of lantibiotics and is referred to as nisin F.  
 
Nisin F proved very effective in vitro against clinical S. aureus strains isolated from sinusitis 
patients (de Kwaadsteniet et al., 2008). Nisin F, in combination with either lysozyme or 
lactoferrin, has a synergistic effect in vitro (de Kwaadsteniet et al., 2009). Lysozyme and 
lactoferrin are the two most abundantly secreted antimicrobial proteins in airway secretions of 
humans (Brogan et al. 1975; Harbitz et al. 1984; Wilson 2005). These in vitro results 
prompted an investigation towards the antimicrobial potential of nisin F against S. aureus 
infections in the respiratory tract.  
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The antimicrobial effect of nisin F was tested in vivo in non-immunosuppressed and 
immunosuppressed Wistar rats. Nisin F or physiological sterile saline (control) was applied 
intranasally to S. aureus infected rats. Histology of non-immunosuppressed rats infected with 
S. aureus K revealed that the rats were healthy. The immune system of rats must therefore be 
compromised for studying S. aureus respiratory tract infections as Kruzsweska et al. (2004) 
concluded during a previous study with cotton rats.  
 
Bacterial infected, immunosuppressed and saline treated rats had the following symptoms of 
respiratory tract infection. Histology detected pneumoniae in the lungs, i.e. obliterated alveoli 
probably due to the infiltration of macrophages, granulocytes and lymphocytes, and the 
proliferation of fibroblasts and alveolar epithelial cells; and mucosal hyperplasia in the 
trachea. Mucosal hyperplasia occurs usually due to an increased mucus production, a 
characteristic of staphylococcal infections (Dohrman et al. 1998; Basbaum et al. 1999). 
Necrotic lesions were also visible on the lungs and blood contamination was detected in one 
of the rats, indicative of damage lung tissue through which the pathogen migrates into the 
blood stream. None of the above mentioned symptoms were detected in the infected, 
immunosuppressed and nisin F-treated rats. This indicated that nisin F protected the 
respiratory tract of the rats. No bacteremia, necrotic lesions, mucosal hyperplasia or 
pneumoniae were recorded.  
 
Kokai-Kun et al. (2003) applied nisin intranasally, in a petroleum-based cream formulation, to 
cotton rats infected with S. aureus. Nisin was unable to eradicate S. aureus from the nares of 
the rats although it had antistaphylococcal activity in vitro.  Researchers concluded that nisin 
was either inactivated or absorbed in the nares since no antistaphylococcal activity could be 
detected from the nares of the nisin-treated rats. This study focused on the effect of nisin on 
the colonization of S. aureus in the respiratory tract of rats and hence did not include clinical 
parameters such as bacteremia or histopathology. The other difference between the Kokai-
Kun et al. and our study is that nisin was applied in a cream formulation in their study and 
during our investigation nisin was applied in a water-based formula. Kruszewska et al. (2004) 
also investigated the effect of a lantibiotic, mersacidin, on the colonization of the nares of 
immunosuppressed mice with S. aureus. Mersacidin was successful in eradicating S. aureus 
from the nares. Interleukin 1 was not detected in mersacidin-treated mice. The missing 
immune reaction is also indicative on the curative effect of mersacidin.  
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The safety of administering nisin F intranasally had to be evaluated. The joint FDA/WHO 
Expert Committee on Food additives (JECFA) have only declared nisin A and Z to be safe for 
human consumption (WHO, 1969). Nisin F was shown to have no known adverse effects in 
the respiratory tract of Wistar male rats (de Kwaadsteniet et al., 2009). The intranasal 
administration of nisin F had no effect on weight gain or on the amount of food and water 
consumed. The lungs, trachea and bronchi of rats (non-immunosuppressed and 
immunosuppressed) treated with nisin F revealed no histopathology and was similar when 
compared to the control groups (saline treated rats). Nisin F had no hemolytic activity in vivo 
since the red blood indices between the nisin-treated and control groups were similar (non-
immunosuppressed and immunosuppressed rats). Nisin F also had no effect on white blood 
cells, lymphocytes and neutrophils production since the levels between the nisin-treated and 
control groups (non-immunosuppressed and immunosuppressed rats) were comparable. 
Concluded from these findings, the intranasal administration of nisin F is safe and nontoxic. 
This endorses the use of nisin F in the treatment of respiratory tract infections.  
 
Newly developed methodology, bioluminescent imaging (BLI), was used to monitor the 
effect of nisin F against S. aureus-related infections in real-time, noninvasively in live animals. 
Nisin F is active against S. aureus Xen 36, a strain engineered with the luxABCDE operon 
integrated at a single site on a native plasmid. Non-immunosuppressed and 
immunosuppressed C57BL/6 mice were infected with S. aureus Xen 36 intranasally and 
imaged in the IVIS 100 System for bioluminescence. The immune system of the mice was 
suppressed with either deksamethasone or 3 Gy X-ray irradiation. Unfortunately, the 
bioluminescence detected in the mice was not consistent and thus not reproducible. The 
parental strain of S. aureus Xen 36 was S. aureus ATCC 49525, a clinical strain isolated from 
a bacteremia patient. It is possible that S. aureus Xen 36 were unable to colonize the 
respiratory tract of the mice since it was not originally a nasal isolate, unlike S. aureus K used 
in the Wistar rat model.  
 
 The advantage of studying skin and subcutaneous skin infections with BLI technology is that 
the infections is on the surface of the C57BL/6 mice since photon intensity decreases ten fold 
with each centimeter of tissue depth (Sadikot and Blackwell, 2005). The bioluminescent 
bacteria, S. aureus Xen 36, was easily detected and monitored. S. aureus Xen 36 injected 
subcutaneously also successfully infected the mice since this strain was originally isolated 
from a bacteremia patient, as already mentioned.  In this experiment C57BL/6 mice were 
grouped into four groups; infected nisin-treated mice, infected saline treated mice, 
 101 
noninfected nisin-treated mice and noninfected and nontreated mice. The immune system of 
all the mice was suppressed by adding deksamethasone to their drinking water throughout the 
duration of the trail. Mice were treated with either nisin F or sterile physiological water 24 h 
and 48 h after infection with subcutaneously injected S. aureus Xen 36.   
 
The bioluminescence flux measurements (total photon emmisions) between the infected, 
nisin-treated mice and the infected, saline treated mice did not differ significantly. Histology 
of skin tissues revealed that both groups of mice suffered from subacute to active dermatitis 
with multifocal areas of necrosis in the dermal stromas and deeper subcuticular tissues. The 
only difference was the higher number of polymorphonuclear cells detected in the lesions of 
the infected, nisin-treated mice. Nisin F was therefore ineffective in combating subcutaneous 
staphylococcal infection. The bioluminescence flux measurements of the non-infected, nisin-
treated mice and non-infected and non-treated mice were significantly lower than the 
measurements of the infected mice groups, as expected. Histology of skin tissues of 
noninfected, nisin-treated mice detected symptoms ranging from no changes to focal acute 
dermatitis.  Focal areas of oedema with mild infiltration of polymorphonulear cells as well as 
a few mast cells were detected in the dermal stroma of the mouse with focal acute dermatitis 
and the mouse with mild focal oedema. No histological changes were observed in the skin 
tissues of noninfected and nontreated mice.  
 
Mice treated with nisin (both the infected and noninfected groups) had a higher number of 
polymorphonuclear cells in the dermal stromas of the skin tissue. This indicates that nisin F 
may have stimulated the immune system when injected subcutaneously. These are only 
preliminary results and must be further investigated since the interest of nisin and other 
lantibiotics as medical antimicrobials are growing. Atopic dermatitis is initiated and 
maintained by the actions of inflammatory cells such as cytokines, chemokines and T-cells 
(Chan, 2008). Great care must therefore be taken since subcutaneously injected nisin, if acting 
as an immune modulator, could worsen atopic dermatitis.  
 
Future research will include investigating the effect of nisin F as a topical antimicrobial on 
superficial skin infections. The noninvasive application of nisin F as a topical agent will not 
only determine if it is more effective as an antimicrobial but will also investigate whether the 
innate immune system will also be aggravated. Nisin F can also be incorporated in chitosan 
acetate bandages, already used in wound dressing, to investigate whether it will increase the 
antimicrobial efficiency. Burkatovskaya et al. (2006) used BLI to investigate whether 
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chitosan acetate bandages prevented bioluminescent S. aureus, Proteus mirabilis and 
Pseudomonas aureuginosa from infecting wounds.  
 
To conclude, nisin F is a new natural nisin variant produced by L. lactis subsp. lactis, isolated 
from the freshwater catfish, Clarias gariepinus. Nisin F has shown antimicrobial activity 
against clinical S. aureus strains in vitro and the antimicrobial properties were further tested in 
vivo using murine models. Nisin F, applied intranasally, protected the respiratory tract of rats 
against S. aureus K. Nisin F applied intranasally proved to have no adverse effects on the 
respiratory tract and hence safe for use. Subcutaneously injected nisin F was however unable 
to protect mice against deep dermal staphylococcal infection, S. aureus Xen 36 being the 
causative agent. Also, the safety of subcutaneously injected nisin F is questionable since it 
may have modulated the immune system of the mice. Nisin F treatments had different 
outcomes, depending on the site of infection and the route of administration. Nisin F as an 
alternative treatment for S. aureus related infections have displayed positive and negative 
results. This area of research has only recently developed and these preliminary results need 
to be verified by more in-depth research since animals and humans are complex systems.  
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